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Abstract: Epigenetic mechanisms affecting chromatin structure contribute to regulate gene expression and assure the inheritance of in-
formation, which are essential for the proper expression of key regulatory genes in healthy cells, tissues and organs. In the medical field, 
an increasing body of evidence indicates that altered gene expression or de-regulated gene function lead to disease. Cancer cells also suf-
fer a profound change in the genomic methylation patterns and chromatin status. Aberrant DNA methylation patterns, changes in chroma-
tin structure and in gene expression are common in all kind of tumor types. However, studies on leukemias have provided paradigmatic 
examples for the functional implications of the epigenetic alterations in cancer development and progression as well as their relevance for 
therapeutical targeting.  
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INTRODUCTION 
Epigenetic mechanisms such as DNA methylation, post-
translational modifications of histone proteins and remodeling of 
nucleosomes affect chromatin structure and contribute to define 
heritable changes in gene expression. In healthy cells, tissues and 
organs, a proper chromatin structure is indeed essential for the cell 
and tissue specific control of gene expression and for the recogni-
tion and actual accessibility of specific DNA sequences to chroma-
tin-associated proteins, including transcription factors [1]. The nu-
cleosome is the basic unit of chromatin, which consists of 146 bp of 
DNA wrapped around an octamer of core histone proteins: histone 
2A (H2A), histone 2B (H2B), histone 3 (H3) and histone 4 (H4). 
The dynamic modulation of the chromatin structure is mainly 
caused by the activity of different chromatin remodeling enzymes 
including DNA methyl-transferases (DNMTs), proteins binding 
methylated DNA (MBDs), histone acetyl-transferases (HATs), 
histone de-acetylases (HDACs), histone methyl-transferases 
(HMTs) and histone de-methylases (HDTs), which generate a par-
ticular array of marks on DNA and histones. These enzymes cause 
chromatin modifications by affecting: i) the methylation status of 
cytosine in the DNA CpG dinucleotide (DNMTs); ii) the amino 
terminal tails of the core histones that protrude through the DNA 
and are exposed on the nucleosome surface, including, acetylation 
and deacetylation of lysines, methylation and demethylation of 
lysine and arginines (HAT, HDACs, HMTs, HTDs), phosphoryla-
tion of serines and threonines and others; iii) the adenosine triphos-
phate-dependent SWI/SNF complex [1-3]. Specific molecular 
modifications on CpGs and nucleosomal histones affect the higher-
order chromatin architecture and function by changing the interac-
tion of histones with DNA or the contact between different histones 
in adjacent nucleosomes. This allows or denies the accessibility of 
the transcriptional machinery and of transcription factors to their 
specific sites on gene promoter regions. This activates or silences 
the transcription and the expression of genes including those in-
volved in cell determination and tissue specificity (Fig. 1).  
Deregulation of epigenetic mechanisms of gene expression may 
be as relevant as genetic alterations for the development and pro-
gression of cancer and leukemia. Epigenetic deregulation can also 
cooperate with genetic alteration in tumor and leukemia establish-
ment and progression. Indeed, dysfunctional epigenetic mecha-
nisms controlling gene expression, have acquired great importance 
as oncogenic factors per se and are considered common marks for 
tumor cells [4, 5].  
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Epigenetic transcriptional silencing of genes required for prolif-
eration and differentiation of the hematopoietic cell are likely to 
contribute to the leukemogenic event underlying myelodysplastic 
syndromes (MDS) and acute myeloid leukemias (AML). In these 
diseases, epigenome-modifying enzymes such as HDACs, HATs 
and DNMTs contribute to transcriptional de-regulation as the con-
sequence of their aberrant recruitment or function at specific target 
gene promoter sites. In this view, altered DNA methylation patterns 
and histone marks are not only of importance to our understanding 
of the molecular pathogenesis of these diseases but may also serve 
as novel markers for their diagnosis, prognosis, and prediction of 
response to therapy [6, 7]. 
Moreover, the potential reversibility of the DNA and chromatin 
modifications makes chromatin remodeling enzymes attractive 
targets for therapeutic intervention, opening up new horizon for the 
treatment of MDS and AML. Two classes of epigenetic drugs are 
today available in clinical settings, which act through the inhibition 
of the enzymatic activities responsible for epigenetic transcriptional 
silencing, the DNMTs and the HDACs, respectively. Re-expression 
of silenced oncosuppressor genes represents the final aim of epige-
netic therapy, but it is not excluded that these drugs may also act 
through different mechanisms. 
Epigenetic Changes in Normal and Neoplastic Cells 
The methylation of cytosine of CpG dinucleotide, within DNA 
regions of 0.2-5 Kb, heavily enriched for CpG dinucleotides 
(known as CpG islands), mainly located in promoter regions, is a 
major epigenetic mechanism of transcriptional control, which is 
dysregulated in human cancer. In normal cells, cytosines within 
CpG islands are usually unmethylated, whereas CpG dinucleotides, 
mainly localized in repetitive, centromeric regions, are methylated. 
The lack of methylation in promoter-associated CpG islands allows 
gene transcription to occur by providing both the formation of an 
active chromatin status and the binding of appropriate transcription 
factors [6]. Methylation of promoter CpG islands is associated with 
an inactive chromatin structure and transcriptional silencing of the 
associated gene [6, 8, 9].  
CpG methylation is catalysed by a family of enzymes known as 
DNA methyltransferases (DNMTs) that add a methyl group to the 
carbon 5’ position of the cytosine ring in the palindrome CpG 
dinucleotide [10, 11]. DNMT-1 is a maintenance methylase that 
recognizes and methylates hemi-methylated CpG dinucleotides 
during DNA replication allowing the propagation and conservation 
of DNA methylation patterns through the future generations [12]. 
DNMT-3a and -3b are de novo methylase and methylate unmethy-
lated CpG dinucleotides [13]. 
DNA methylation patterns are established during the embryo-
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antee not only transcriptional silencing, a condensed chromatin 
structure and chromosome X inactivation in women, but also ge-
nomic stability through suppression of homologous recombination 
between repetitive sequences [1]. Looking at development, it has 
been shown that most germline-specific genes are later on methy-
lated in somatic cells, suggesting additional functional selection, 
during differentiation [14].  
In cancer cells aberrant promoter hypermethylation coexists to-
gether with global hypomethylation [7, 15]. The hypomethylation 
of pericentromeric and centromeric regions, repetitive elements and 
integrated/silenced viral sequences exerts the oncogenic effect 
through reactivation of silenced sequences and of oncogenes [16, 
17]. On the other hand, aberrant hypermethylation of promoter CpG 
islands leads to transcriptional silencing of known or candidate 
tumour suppressor genes [6, 8, 9]. The frequency of this process, 
the variety of genes involved, and the large repertoire of cancers 
shown to harbour dense methylated promoter CpG islands all re-
flect the critical role of this epigenetic mechanism in cancer initia-
tion and progression. Some genes have been shown to be hyper-
methylated in many tumour types, but in general, the pattern of 
genes hypermethylated in cancer cells is tissue specific and not 
random [7]. Many fundamental components of key cellular path-
ways are inactivated in human cancer by hypermethylation includ-
ing: DNA repair (MLH1, MGMT, BRCA1), cell cycle (p16INK4a, 
p15INK4b, p14Arf), cell invasion and adherence (E-cadherin, APC, 
CDH13, VHL), apoptosis (DAPK1, caspase 8), detoxification 
(GSTP1) and hormonal response (retinoic acid receptor 2 and 
estrogen receptor). The deregulation of such pathways is likely to 
confer a survival advantage to the affected cell and thus to contrib-
ute to the step-wise progression towards carcinogenesis [7, 8].  
However, the effects of CpG island promoter methylation on 
transcription depend not only on DNA methylation, but also on 
additional epigenetic events such as modification of histone tails 
and recruitment of methylated DNA binding proteins [18]. Chroma-
tin remodeling involves proteins with high affinity for methylated 
CpGs, known as methyl CpG binding proteins MeCP2, MBD1, 
MBD4 and Kaiso, which mediate the inhibitory effect of CpG is-
land methylation on gene expression acting as transcriptional rep-
ressors. Methyl CpG binding proteins are also often part of large 
co-repressor complexes comprising, NuRD, NoRC, N-Cor, mSin3A 
and SWI-SNF [19-22]. These repressor activities also recruit 
HDACs and HMTs on methylated targeted promoter sequences. 
The consequent post-translational modification of histone tails in-
duced by these enzymes determines a silenced transcriptional status 
of chromatin [1, 18, 19, 23]. 
In vitro studies suggest that HAT and HDACs can target several 
 amino groups of evolutionary conserved lysine residues present 
on N-terminal region of nucleosomal histone H3 and H4 [24]. The 
acetylation of lysine residues on the N-terminus of histones by 
HATs has the most potential to unfold chromatin and is generally 
associated with activation of transcription. Most HATs can also 
acetylate proteins other than histones [25-27].  
In contrast, the HDACs induced de-acetylation of lysine resi-
dues on histones (and potentially on other proteins), has the poten-
tial to compact chromatin resulting in transcriptional gene repres-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Schematic representation of epigenetic modifications leading to gene transcriptional regulation. Epigenetic modifications of the histone H3 tails, Lys9 
(K9), Lys14 (K14), Lys18 (K18), Lys56 (K56), Lys27 (K27) are indicated. Ac: acetylation; Me: methylation. White and black circles indicate the un-methylated 
and methylated CpG dinucleotides, respectively. TF: transcriptional factors; RNAPolII: RNA polymerase II; DNMTs: DNA methyltransferases; HDACs: Histone 
deacetylases; MBDs: Methyl-CpG binding protein; RC: transcriptional repressive complex. Arrows indicate the targeting of specific chromatin remodeling 
enzyme activities by DNA methyltransferase inhibitors (DNMT-Is) and histone deacetylase inhibitors (HDAC-Is). 
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sion [28-30]. Mammalian HDACs are grouped into four families: 
the class I, II, III and IV of HDACs. Class I includes HDACs 1, 2, 3 
and 8, which are homologs of the yeast RPD3 protein, whereas 
HDACs 4, 5, 6, 7, 9 and 10 that are related to the yeast Hda 1 pro-
tein form class II. HDAC11 is the unique member of HDAC class 
IV. HDAC class III includes recently identified mammalian ho-
mologs of the yeast Sir2 protein. In cells, HDACs are present as 
subunits of multiprotein complexes. The cellular sublocalization of 
HDAC class I is constitutively nuclear and dynamically affects 
gene regulation, while HDAC class II translocates from the cyto-
plasm to the nucleus in response to external stimuli. HDAC class I 
and II interact with adaptor protein like mSin3A and transcriptional 
co-repressors N-CoR and SMRT to repress gene transcription [31].  
HMTs methylate specific lysine or arginine residues on nu-
cleosomal histone H3, which in the case of lysine 9 (K9) methyla-
tion allows the recruitment of the heterochromatin protein 1 (HP1) 
stabilizing an inactive condensed chromatin [3]. Histone tail modi-
fications and DNA methylation gather to assemble chromatin struc-
ture, which dynamically shift from a transcriptional permissive state 
to a transcriptional inactive state and viceversa [32]. Hypermethy-
lated and silenced genes in cancer are known to have key histone 
modifications in their promoter regions (i.g. the deacetylation of 
K9, demethylation of K4 and methylation of K9 and K27 on his-
tone H3) [28, 34, 35].  
Acute Myeloid Leukaemia and Myelodysplastic Syndromes 
Whereas aberrant DNA methylation patterns, changes in chro-
matin structure and in gene expression are common in different 
tumor types, studies on leukemias have provided paradigmatic ex-
amples for the functional implications of genetic and epigenetic 
alterations in cancer development. Several studies have shown that 
methylation-associated silencing inactivates certain tumour sup-
pressor genes as effectively as mutations and that it may act as one 
of the cancer predisposing hits described in Knudson’s two-hit hy-
pothesis [9, 36, 37]. Indeed, oncogenic fusion proteins resulting 
form chromosomal translocations associated to acute myeloid leu-
kemias (i.e. PML/RAR, AML1/ETO), exert their oncogenic effect 
by an aberrant recruitment of repressor complexes, containing 
DNMT and HDAC activities, on genes that are relevant for hema-
topoietic differentiation [31]. Moreover, missense mutations, rear-
rangements or inactivation by oncogenic proteins of histone acetyl-
transferase activities (HATs) such as CREB Binding Protein (CBP) 
or p300 have also been reported in leukemias [38, 39]. Suppression 
of -catenin (CTNNA1) expression by both methylation and his-
tone deacetylation has been shown to contribute to the growth ad-
vantage in human MDS or AML with del(5q) [40]. Similar to acute 
promyelocytic leukemia, the differentiation block due to the t(8;21) 
translocation is the result of the recruitment by AML1/ETO of 
chromatin remodeling enzymes, leading to epigenetic silencing of 
the microRNA miR-223 [41]. 
Many genes, important for most of the carcinogenic pathways, 
are frequently hypermethylated in MDS and AML (Table 1). Ac-
cordingly, it has been shown that DNMT1 and DNMT3A are over-
expressed in MDS and AML samples, when compared to controls 
[42]. Among proliferation markers, the tumor suppressor gene p15 
(CDKN2B), a cyclin dependent kinase inhibitor, target of TGF, 
important for the G1/S phase transition of the cell cycle, has been 
shown to be hypermethylated in 40-80% of MDS [43]. The pattern 
of methylation was not different between hematopoietic progenitor 
cells and differentiated cells [44] and was associated to poor sur-
vival [45]. Furthermore in acute myelogenous leukemia, increased 
p15 methylation levels were found in CD34+ cells of many leuke-
mic patients in haematological remission and was associated with a 
high relapse rate and significantly reduced relapse-free survival 
[46]. 
Gene promoter hypermethylation is not always associated to 
poor prognosis. Higher levels of methylation in multiple genes 
(NOR1, NPM2,OLIG2, HINI, SLC26A4) were found in patients 
with good prognosis AML, while no significant difference in meth-
ylation of p15, CDH13 and PGR was found between good and poor 
prognosis groups [Kroeger et al. ASH 2007, Blood 110, Abstract 
#595]. These data suggest that methylation does not always have 
the same prognostic significance.  
Increased angiogenesis has been shown to be involved in the 
pathogenesis of MDS, accordingly we found hypermethylation of 
the anti-angiogenic protein thrombospondin in 6% of MDS, espe-
cially those with a intermediate-2/high IPSS score (unpublished 
observation). Similarly the metastasis suppressor gene E-cadherin 
(CDH1), which binds to - and -catenin, has been shown to be 
hypermethylated in one third of MDS samples [47].  
Table 1.  Genes Hypermethylated in MDS and AML 
 
Pathway Gene  MDS  AML 
Cell cycle  CDKN2B (p15) 50-80%  30-71% 
SOCS1  11 - 31%  0-60% 
RASSF1A 9%  -  Signal transducers 
SHP-1 -  11% 
30-70% 13-64% 
Angiogenesis 
E-cadherin (CDH1) 
Thrombospondin  6% - 
DAP-kinase 7-17%  3-27% 
Apoptosis 
p73 -  10  -37% 
MGMT 2%  5% 
BRCA1 -  38%  DNA repair 
MLH1 -  4% 
83%  71 – 95% 
19%  40 – 69%  Hormones and H-receptors 
Calcitonin (CALCA) 
Estrogen receptor 
Retinoic acid receptor 2  -  18 - 43% 
Detoxification GSTP1  -  18% 
Others HIC1  32%  10% Epigenetic Treatment of Myelodysplastic Syndromes  Current Medicinal Chemistry,  2008 Vol. 15, No. 13      1277 
PHARMACOLOGY OF HYPOMETHYLATING AGENTS 
Epigenetic changes in malignancy are potentially reversible by 
therapeutic inhibition of DNA methylation or histone deacetylation 
and the differential methylation of CpG islands is now a target for 
therapy [48]. The rationale for pharmacological reversion of the 
methylator phenotype is the reactivation of tumour suppressor gene 
expression. The hypomethylating agents, azacitidine and decitabine 
were shown to inhibit DNMT1, leading to induction of expression 
of silenced genes [48], to cause growth inhibition and modest dif-
ferentiation of transformed myeloid cell lines and primary leukemic 
blasts in vitro [49], and to produce clinical responses in AML and 
MDS patients in vivo. Both azacitidine and decitabine are the first 
drugs specifically approved by the USA Food and Drug Admini-
stration (FDA) for the treatment of MDS. Such agents offer a novel 
therapeutic approach, which is less intensive than standard chemo-
therapy. Clinical trials using DNMT inhibitors alone or in combina-
tion with HDAC inhibitors recently yielded promising results in 
patients with other haematological malignancies [7, 48]. 
General Features and Mechanisms of Action of Hypomethylat-
ing Agents 
Azanucleotides are cytidine analogues modified in position 5 of 
the pyrimidine ring with the presence of a nitrogen atom substitut-
ing a carbon. Azacitidine (5-azacytidine, Vidaza
TM, Pharmion Cor-
poration, Boulder, CO, USA) and decitabine (5-aza-2’-
deoxycytydine, Dacogen™, MGI PHARMA, Inc., Bloomington, 
MN, USA), first synthesized in the early 1960s, by Sorm and co-
workers [50, 51], are the best-charactherized drugs belonging to this 
class. At high doses, azacitidine and decitabine are cytotoxic, like 
other cytidine analogues such as cytarabine. However it was later 
found that the ability of these drugs at low doses to inhibit DNMT1 
and cause DNA hypomethylation, thereby restoring normal func-
tion to genes that have a key role in the control of cellular differen-
tiation and proliferation [52-54]. Indeed, concentration of 
azacitidine and decitabine required for maximum inhibition of 
DNA methylation in vitro were not shown to suppress DNA syn-
thesis [55]. Several other compunds were shown to have demethy-
lating activity, including 5-fluoro-2’-deoxycytidine, procaine, pro-
cainamide, hydralazine and (-)-epigallocatechin-3-gallate, but all 
these drugs have been so far less effective than the first azanucleo-
tides [56]. 
Both azanucleotides are pro-drugs: following uptake into the 
cell by nucleoside-specific transport mechanisms, azacitidine and 
decitabine are phosphorylated to monophosphate derivative by 
uridine-cytidine kinase and deoxycytidine-kinase, respectively, and 
then to diphosphate and triphosphate derivatives by pyrimidine 
monophosphate and diphosphate kinases. 5-azacytidine triphos-
phate is incorporated into RNA, disrupts nuclear and cytoplasmatic 
RNA and inhibits protein synthesis, while 5-aza-2’deoxycytidine 
triphosphate is incorporated into replicating DNA, and inhibits 
DNA methylation at low doses and DNA synthesis at high doses. 
Moreover, 5-azacytidine diphosphate is reduced by ribonucleotide 
reductase to 5-aza-2’deoxycytidine diphosphate, which is then 
phosphorylated to 5-aza-2’deoxycytidine triphosphate and incorpo-
rated into DNA (Fig. 2). As a result, while decitabine derived 
triphosphate azanucleotides are incorporated into DNA only, 
azacitidine derived triphosphate azanucleotides are incorporated 
both into DNA and RNA [55, 57]. After integration into DNA of 
replicating cells, the 5-azacytosine ring covalently bind the man-
tainance methyltransferase DNMT1 that is then polyubiquitinated 
and targeted for degradation in the proteosome [58]. In this way, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Intracellular methabolic pathways of azacitidine and decitabine. After cellular uptake, both drugs require phosphorilation to triphosphate derivates to 
be incorporated respectively into newly synthesized RNA and DNA. 5-azacytidine diphosphate is also reduced by ribonucletide reductase to 5-aza-
2’deoxycytidine diphosphate which is furthermore phosphorilated and incorporated into DNA. Then, the 5-azacytosine rings bind covalently the DNMT1 and 
the resulting adducts are excised from DNA, ubiquitinilated and targeted to proteosome for degradation, inducing the lost of methylation in one of the DNA 
daughter molecules and re-expression of silenced genes. Azacitidine also induces RNA degradation and inhibition of protein synthesis while both drugs at high 
doses block the DNA synthesis. 
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DNMT1 is no more available to remethylate hemi-methylated sites 
created during DNA replication, and methylation is passively lost in 
one of the daughter DNA molecules during cell division, inducing 
re-expression of gene silenced by promoter hypermethylation [59]. 
Since in cancer cell DNA methylation usually affects tumor sup-
pressor genes which are genetically intact, their reactivation after 
demethylation completely restores their normal functions. Demeth-
ylating agents were also shown to induce in tumor cells can-
cer/testis and viral antigens, that may represent a target for humoral 
and CD8+ T immune response against tumor, providing opportuni-
ties for immunotherapeutic targeting [60, 61]. 
While the demethylating effect depends on incorporation of de-
rived deoxy-azanucleotides into DNA, azacitidine-induced cytotox-
icity is mainly due to incorporation into RNA in the cell cycle 
phase G1 at low drug concentrations and to the incorporation into 
both RNA and DNA in the G1 and S phases of the cell cycle at 
higher concentrations of azacitidine [62]. On the other end, decit-
abine is a phase-S specific drug because its activity is exclusively 
related to incorporation into DNA of replicating cells.  
Major mechanisms of resistance to azanucleotides are repre-
sented by increase in cytidine deaminase, the enzyme that inactives 
both drugs [63]. Zebularine (1-(Beta-d-ribofuranosyl)-1,2-
dihydropyrimidin-2-one), is an acid stable and oral available nu-
cleoside analogue that endows with unique biologic properties as a 
potent inhibitor of both cytidine deaminase and DNMTs, due to the 
lack of the exocyclic 4-amino group in the pyrimidine ring [64]. 
Although zebularine possesses an independent antineoplastic activ-
ity, this drug was shown to synergize with decitabine in reactivating 
methylated genes and inhibiting proliferation of leukemic cell lines 
in vitro, by blocking decitabine inactivation through cytidine 
deaminase [65]. This combination will offer new options to in-
crease the DNMT inhibitor activity in patients. 
Another attempted approach to inhibit the DNMTs was repre-
sented by a phosphorothioate antisense oligodeoxynucleotide di-
rected against the 3' untranslated region of the DNMT1 enzyme 
mRNA (MG98). This agent was able to inhibit DNMT1 expression 
without effecting DNMT3, causing demethylation with re-
expression of silenced genes in cancer cell lines and tumor growth 
inhibition in mouse models. However, an unfavourable toxicity 
profile and no clinical responses were observed in patients with 
solid tumors treated by MG98 in phase I and II clinical trials [66, 
67]. 
Pharmacological Profile of Azacitidine 
Azacitidine can be administered intravenously (i.v.) or subcuta-
neously (s.c.). Maximum plasma concentrations (Cmax) occur 30 
minutes after s.c. administration and 11 minutes after a 10 minutes 
i.v. infusion. The mean plasma concentration following i.v. infusion 
is approximately 4-fold higher than that following s.c. administra-
tion. The bioavailability after s.c. administration is 89% of that after 
i.v. infusion. The plasma half-life is approximately 22 minutes after 
i.v. infusion and 41 minutes after s.c. administration. The drug is 
widely distributed in tissues with a mean distribution volume of 76 
liters. Azacitidine is very unstable in aqueous solutions, and after 
administration it undergoes rapid deamination by cytidine 
deaminase with subsequent degradation. Azacitidine and its me-
tabolites are mainly excreted by the urinary tract with a mean 
elimination half-life of about 4 hours [68]. There are no data about 
the interaction of azacitidine with other drugs. 
The main target organs of toxicity after treatment with 
azacitidine are the bone marrow and the gastrointestinal tract. 
Common side effects reported by patients after azacitidine treat-
ment include nausea, vomiting, diarrhea, constipation, anorexia, 
injection site events, arthralgia, cough, dyspnea, headache, weak-
ness, dizziness, and insomnia. Hematological toxicity includes 
thrombocytopenia and neutropenia, leading to bleeding and to an 
increased infection risk. In the CALGB 9221 trial, grade 3 and 4 
granulocytopenia occurred in 58% and thrombocytopenia in 52% of 
patients receiving azacitidine. Toxicity was transient and patients 
usually recovered in time for the next treatment cycle. The highest 
proportion of myelosuppression occurred during the first two cycles 
of therapy and decreased in subsequent cycles [68, 69]. 
A peculiar concern about azacitidine mechanim of action re-
gards the hypothetical secondary tumorigenesis related to the drug-
induced global DNA hypomethylation. Mice carrying hypomorphic 
DNMT1 with reduced expression to 10% of wild type levels, show 
genome-wide DNA hypomethylation and develop aggressive T-cell 
lympomas [70]. Moreover studies in vitro and in rodents have 
shown that azacitidine is mutagenic, embryotoxic, teratogenic and 
carcinogenic, as other pyrimidine analogs [71, 72] and azacitidine 
treated rats developed a variety of tumor types, including acute 
leukemia, malignant reticuloendotheliosis, tumors of testis, skin, 
bronchus, and often multiple tumors [73]. So far, there are no pub-
lished reports about secondary malignancies developing following 
azacitidine treatment in humans, but a careful and longer follow-up 
and the growing number of treated patients will clarify this issue.  
An oral formulation of azacitidine in now available by Phar-
mion Corporation (Boulder, CO, USA) and a Phase 1 clinical trial 
is ongoing to assess safety, tolerability, bioavailability and pharma-
cokinetics of escalating single doses in patients with MDS and 
AML [ClinicalTrials.gov Identifier: NCT00528983]. A pharma-
cokinetic study carried out in dogs treated with oral azacitidine 
demonstrated rapid absorption with absolute bioavailability of 67% 
and plasma concentrations similar to those obtained with parental 
doses [Ward et al. ASCO2007, Abstract #7084]. 
Pharmacological Profile of Decitabine 
Decitabine is available for i.v. administration. Oral administra-
tion is not optimal due to the rapid decomposition in acid. There is 
an excellent distribution of decitabine in the body fluids after i.v. 
injection with rapid equilibration between the extracellular and 
intracellular compartments [74]. Decitabine crosses the blood-brain 
barrier and during a continuous i.v. infusion the level of this ana-
logue in the cerebral spinal fluid is about half the plasma level [75]. 
Clearing of meningeal leukemia was observed in a patient treated 
with decitabine continuous intravenous infusion [76].  
In the most common schedule used for MDS and AML, decit-
abine was administered at a dose of 15 mg/m
2 as a 3 h i.v. infusion 
every 8 h for three consecutive days of a 6-week cycle, with a total 
dose per cycle of 135 mg/m
2 [77, 78], but several other schedules of 
administration have been studied [79]. After a single 15 mg/m
2 3 h 
i.v. infusion, Cmax is 64.8–77.0 ng/ml and is generally reached at 
the end of infusion. The mean area under the plasma concentration-
time curve (AUC) range from 152 to 163 ng h/ml. Steady state in 
plasma is reached by the end of 3 h infusion. The terminal phase 
elimination half life (t1/2) is approximally 35 minutes and no sys-
tematic accumulation of the drug occurs during repeated dosing due 
to the short t1/2. The mean total body clearance values were 125-132 
l/h per m
2, indicating that both hepatic and extrahepatic metabolism 
are involved in elimination of decitabine. Cytidine deaminase plays 
the major role in the deactivation process by deamination of decit-
abine. The mean values of distribution volume at steady state 
ranged from 62.7 to 89.2 l/m
2 [74, 80]. 
Decitabine is generally well tolerated and has a favorable toxic-
ity profile. Myelotoxicity is the most important adverse effect ob-
served in patients who received decitabine therapy. Most episodes 
of febrile neutropenia and sepsis occurred in MDS patients during 
the first or second cycle of therapy, when neutropenia due to both 
therapy and/or disease was present. Less common side effects in-
clude nausea, vomiting, anorexia, mucositis, alopecia, liver toxicity, 
renal failure, atrial fibrillation, seizures, sleep disorder, deafness 
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Chromosomal aberrations and single-strand breaks in DNA 
have been detected in cells after treatment with decitabine, although 
the single-strand DNA breaks may represent a repair mechanism to 
remove DNMT adducts containing 5-azacytosine from DNA [81, 
82]. As for azacitidine, concerns exist about a possible carcinogenic 
effect of drug-induced global genome hypometylation. Neverthe-
less, it was shown that pharmacologically induced demethylation is 
only transient with restoration of normal methylation levels in few 
weeks after stopping therapy [83], and decitabine has shown neither 
significant mutagenic activity in vitro nor carcinogenic properties in 
vivo [74]. Moreover mice with a genetic predisposition to develop 
colon or lung cancer showed a marked reduction in tumor forma-
tion when treated with decitabine, suggesting some chemopreven-
tive potential [84].  
PHARMACOLOGY OF HDAC INHIBITORS 
General Features and Mechanisms of Action of HDAC Inhibi-
tors 
After the first observations about the antitumoral activity of 
trichostatin A and trapoxin, whose HDAC inhibiting activity was 
later discovered [85, 86], a relatively wide range of compounds 
deriving from both natural sources and from synthetic routes, have 
been identified to be able to inhibit the activity of class I, class II 
and class IV HDACs [31, 87]. Most of these HDAC inhibitors 
(HDACIs) work equally well against all HDACs, but some of them 
preferentially inhibit class I versus class II HDACs. Howerver, 
despite a different HDAC isoenzyme inhibition profile and pharma-
cological properties, all HDACIs show similar patterns of cellular 
response, and there is no definitive evidence that distinct HDACs 
have a defined role in cancer [88]. 
The active site of all HDAC consists of a narrow tubular pocket 
with a zinc atom inside. Despite the variety of their structural char-
acteristics, HDAC inhibitors can be broadly characterized by a 
common “pharmacophore” model which consists in a surface do-
main (also named “CAP”), which is able to interact with the rim 
space at the entrance of the catalytic tunnel of the enzyme, linked to 
a hydrophobic spacer through a polar connection unit. At the end of 
the hydrophobic spacer, a zinc-binding domain assures the inhibi-
tion of enzyme activity. Since structural features around the active 
site are well conserved across all the HDACs, except for the rim of 
the catalytic pocket, changes of CAP and/or connection unit might 
justify different potency and selectivity of HDAC inhibitors [89, 
90]. 
After HDAC inhibition with the resulting hyperacetylation of 
lysine residues in the histone tails, chromatin structure shifts to a 
transcriptionally active state, with re-expression of silenced genes. 
It is thought that from 5 to 20% of all known genes are affected by 
HDACIs [91-93]. However, acetylation works together with other 
post-translational modifications, and blocking deacetylation might 
have very different outcomes depending on the previous chromatin 
state. Additionally, since a growing number of non-histone proteins 
are recognized being HDAC substrates, it is likely that part of 
HDACI effects on cellular profile might be independent of chroma-
tin state modification. Indeed, there are multiple mechanisms by 
which HDACIs can influence the expression of a protein, other than 
the level of mRNA production, such as modifying stability of the 
protein by altering chaperone protein function or preventing ubiq-
uitinilation and proteosome degradation. Moreover HDACIs may 
interfere with the subcellular localization, DNA-binding activity, 
protein-protein interaction of several non histone proteins, such as 
transcription factors or signal transducers, by increasing their acety-
lation [31]. 
HDACIs induce, to a variable extent, growth arrest, differentia-
tion or apoptosis in vitro and in vivo. Growth arrest is usually in-
duced at low doses, while apoptosis occurs at higher doses. 
HDACIs induce cytoxicity in a broad selection of tumor and normal 
cell lines, both in cycling and non-proliferating cells, although 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Chemical structure of different classes of HDAC inhibitors entered in clinical trials.  
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higher drugs concentration are required to kill arrested cells [31]. 
Normal cells usually show a strikingly reduced sensitivity to 
HDACIs treatment, hinting at potentially large differences in the 
acetylome in normal versus tumour cells [94].  
HDACI-induced growth arrest is tightly linked to the induction 
of p21, through both hyper-acetylation of chromatin at the 
CDKN1A (which encodes p21) promoter and transcriptional activa-
tion of CDKN1A [95, 96]. HDACIs also induce cell death through 
caspase-dependent and caspase independent pathways, and through 
the accumulation of reactive oxygen species (ROS) [97, 98]. Ex-
pression of thioredoxin, a ROS scavenger, in normal cells but not in 
transformed cells might in part justify the reduced sensitivity of 
normal cells to HDACIs treatment [94]. It was also highlighted the 
role of BAX in HDACIs induced apoptosis, since BAX-/- murine 
fibroblast were shown to be resistant to HDACIs. It was demon-
strated that the DNA damage associated protein, Ku70, in its deace-
tylated form (maintained by several HDACs), keeps BAX away 
from the mitochondrion and protects cells from apoptosis. Treating 
cells with HDACIs induces hyperacetylation of Ku70 through the 
HATs, leading to dissociation of the complex and translocation of 
BAX to the mitochondria with activation of the intrinsic pathway of 
apoptosis [99, 100].  
Since acetylation of core histones has been correlated with 
chromatin assembly, DNA repair and recombination, HDACIs were 
shown to inhibit also DNA repair responses in cell lines, which 
might increase the sensitivity of tumour cells to chemotherapy and 
radiotherapy by leading to increased DNA damage by these treat-
ments [101, 102].  
Several thousands of molecules, screened by in vitro assays, 
have been so far shown to have HDAC inhibitory activity. However 
HDACIs entered in clinical trials can be divided into four chemical 
classes including short chain fatty acids, hydroxamic acid deriva-
tives, benzamides and cyclic peptides [31] (Fig. 3).  
For the aim of this review, we will discuss only the pharmacol-
ogical properties of HDACIs entered in clinical trials for the treat-
ment of MDS and AML. 
Short Chain Fatty Acids 
These drugs inhibit both class I and IIa HDACs, but usually 
show low potency due to the inability to make significant contact 
with the catalytic pocket of HDACs [103] (Table 2). 
Sodium butyrate is the prototype of this class of compounds, in 
vitro induces growth arrest and differentiation of human leukemia 
cells at millimolar concentrations, but its clinical development has 
been hampered by its short half-life and difficulty in achieving 
millimolar levels in vivo [104].  
Phenylbutyrate is a aromatic fatty acid, able to induce hyperace-
tylation of histones H3 and H4 and growth arrest, differentiation 
and apoptosis of AML cell lines and primary leukemic cells. It has 
been effectively used to induce fetal erythropoiesis in patients with 
sickle cell anemia and -thalassemia [105]. The aromatic ring does 
not contribute to the antitumor activity, as butyric acid is of equal or 
greater potency at producing these biological changes, while short-
ening of the fatty acid carbon chain length, as demonstrated with 
phenylacetate, significantly diminished drug potency [106]. After 
administration phenylbutyrate is metabolized to phenylacetate, then 
to phenylacetylglutamine and eliminated by urine [107]. The 
maximum tolerated doses, when administered as a 7-day continuous 
infusion, was 375 mg/kg/day, while higher doses were associated 
with encephalopathy apparently attributable to accumulation of the 
metabolite phenylacetate. At the maximum tolerated dose (MTD), 
median steady state concentration of phenylbutyrate is 0.3 mM, 
which is less than the ED50 of 1-2 mM required for differentiation 
and cytostasis in vitro but in whitin the concentration range in 
which phenylbutyrate induces acetylation of histones. Dose-limiting 
toxicities were mainly represented by neurocortical toxicity, includ-
ing lethargy, confusion, and slurred speech, which completely dis-
appeared within 24 to 48 h upon cessation of the infusion. Non 
dose-limiting toxicities were hyperammoniemia, hyperuricemia, 
hypocalcemia, skin abnormalities and interstitial pneumonia [108, 
109]. 
Pivaloyloxymethyl butyrate (AN-9, Pivanex
TM, Titan Pharma-
ceuticals, Inc., South San Francisco, CA, USA) is an acyloxyalkyl 
ester pro-drug of butyric acid that undergoes to rapid hydrolysis to 
butyric acid, pivalic acid and formaldehyde, after the cellular up-
take. Its anticancer effect is assumed to stem primarily from the 
inhibition of HDACs by the released butyric acid [110]. AN-9 in-
hibits cell proliferation of a variety of cancer cell lines and primary 
human solid tumor cells. In leukemia cell lines, AN-9 has shown 
differentiating and pro-apoptotic effects [111]. Compared to sodium 
butyrate, AN-9 is at least 10-fold more potent both in vitro and in 
vivo, probably due to its increased permeability across cell mem-
branes, allowing for efficient delivery of butyric acid to subcellular 
targets [112]. Moreover AN-9 has demonstrated more favorable 
toxicological and pharmacological properties than sodium butyrate 
in preclinical studies. In phase I clinical studies in patients with 
advanced solid malignancies, AN-9 was administered by 6-h i.v. 
infusion daily for 5 days every 3 weeks at dosages ranging from 
0.047 to 3.3 g/m
2/day. The most common observed toxicities were 
nausea, vomiting, hepatic transaminase elevation, hyperglycemia, 
fever, fatigue, anorexia, injection site reaction, diarrhea, and visual 
complaints [113].  
Valproic acid (di-n-propylacetic acid) is a short chain fatty acid 
used for decades as a anticonvulsant, whose anticancer activity was 
detected in vitro more than 10 years ago. However, it was only in 
2001 that its antineoplastic effects were shown to depend on its 
inhibitory action on HDACs [114, 115]. Valproic acid inhibits class 
I HDACs (HDAC 1 through 3) and class II HDACs 4, 5 and 7 
Table 2. HDAC Inhibitory Activities of Distinct Drugs 
 
HDAC inhibitor class  Drug 
HDAC1 
IC50 (μM) 
HDAC2 
IC50 (μM) 
HDAC3 
IC50 (μM) 
HDAC4 
IC50 (μM) 
HDAC6 
IC50 (μM) 
HDAC8 
IC50 (μM) 
Short chain fatty acids  Valproic acid [103]  700  800  1000  1500  >20000  n.a 
SAHA [88]  0.021  n.a  0.037  n.a  0.025 1.2 
Hydroxamic acids 
LAQ824/LBH589 [88]  0.0018  n.a  0.0037  n.a  0.015 0.14 
MS-275 [88]  0.18  n.a  0.74  n.a  >100 44.9 
CI-994 [88]   0.41  n.a  0.75  n.a  >100 >100  Benzamides 
MGCD0103 [88]  0.082  n.a  0.62  n.a  >30 >25 
Cyclic peptides  Despipepdide [134]  0.036  0.047  n.a  0.51 14 n.a 
Concentrations that inhibits 50% (IC50) of the activity for each HDAC isoenzyme of distinct HDAC inhibitors. Comparison is only indicative because different HDAC assays were 
used in the reported studies [88, 103, 134]. The IC50 was not available (n.a.) for all the HDAC isoenzymes. Epigenetic Treatment of Myelodysplastic Syndromes  Current Medicinal Chemistry,  2008 Vol. 15, No. 13      1281 
whereas class II HDACs 6 and 10 are not inhibited [103]. In con-
trast to other inhibitors, it induces also proteasomal degradation of 
HDAC2 [116]. Valproic acid induces differentiation of transformed 
hematopoietic progenitors and primary AML blasts, as well as it 
reduces tumor growth and metastases in animal studies [117]. Oral 
bioavailability is nearly 100%, but i.v. administration is possible 
too. It has a small volume of distribution (0.13–0.19 L/kg), the 
plasma half-life is from 9 to 18 hours, and its protein binding is 
from 80% to 95%. Multiple interactions with other drugs have been 
described both at the level of protein binding and drug metabolism 
[118]. Generally, valproic acid is well tolerated. Main reported 
toxicities are neurologic side effects such as sedation, dizziness, and 
tremor, mild gastrointestinal side effects and hematologic toxicity, 
including pancytopenia and severe bone marrow hypoplasia. Liver 
failure and teratogenicity with neural-tube defects have been de-
scribed [117].  
Hydroxamic Acids 
This class includes some of the most potent HDACIs. Accord-
ing to the pharmacophore model, the hydroxamic group chelates the 
zinc atom at the active site of HDACs, while a hydrophobic cap and 
an aliphatic side chain respectively, interacts with the edge and fits 
into the hydrophobic catalytic pocket [89, 90]. Members of this 
class, with trichostatin A (TSA) as the prototype, are potent unse-
lective inhibitors of both class I and II HDACs (Table 2). 
Suberoylanilide hydroxamic acid (SAHA, vorinostat, Zolin-
za
TM, Merck & Co., Inc, Whitehouse Station, N.J., USA) is a sec-
ond-generation hydroxamate compound, which was shown to in-
duce differentiation, growth arrest, or apoptosis of transformed 
human cells in culture at micromolar concentrations, and to have 
antitumor activity in several in vivo models of cancer [119]. In 
HDAC enzyme activity assay, hydroxamates derivatives SAHA and 
LAQ824/LBH589 induce at nM to μM concentration complete 
inhibition of HeLa nuclear extract HDAC activity as well as re-
combinant HDAC1, 3, 6 and 8, although the inhibition of HDAC8 
was significantly weaker [88]. 
Clinical responses to SAHA were observed in phase I trials in 
both refractory solid and hematological malignancies. Increased 
accumulation of acetylated histones in tumors, bone marrow and 
peripheral blood cells was observed during the treatment. SAHA 
was usually well tolerated both i.v. and orally, with different phar-
macokinetics and toxicity profile according to the administration 
pathway. Major adverse events with the oral formulation include 
fatigue, diarrhea, anorexia, and dehydration. Myelosuppression and 
thrombocytopenia are more prominent with SAHA i.v. formulation 
and in patients with hematological malignancies than in those with 
solid tumors. Usually, the hematologic toxicities resolve shortly 
after SAHA stopping. The MTD of SAHA for i.v. administration in 
patients with hematologic malignancies was 300 mg/m
2/d for 5 
days every 3 weeks, while the MTD for the oral formulation was 
400 mg qd and 200 mg bid for continuous daily dosing and 300 mg 
bid for 3 consecutive days per week dosing. At the steady-state of 
equivalent doses, the Cmax of the i.v. formulation is nearly four 
fold greater than the Cmax of the oral formulation, whereas the 
AUC is nearly 22-fold greater for the oral drug. The mean apparent 
t1/2 following oral administration (range 91.6 to 127 minutes) is 
longer than the mean apparent t1/2 following i.v. administration of 
the oral equivalent doses (range 34.7 to 42.4 minutes). After oral 
administration the estimated bioavailability of SAHA is 43% and 
food does not appear to alter substantially the rate or extent of ab-
sorption [120, 121]. On June 2006, SAHA received FDA approval 
for the treatment of advanced cutaneous T-cell-lymphoma (CTCL). 
LAQ824 and the more potent analog LBH589 are novel cin-
namic acid hydroxamates and pan-HDAC inhibitors, developed by 
Novartis. As other HDACIs, at nanomolar concentrations they in-
duce growth arrest and apoptosis of a variety of cancer and leuke-
mia cell types, cause hyperacetylation of H3 and H4 histones, in-
crease p21 levels, and induce cell cycle G1 phase accumulation 
[122]. They have been extensively studied for their ability to induce 
acetylation and to inhibit the ATP binding and chaperone function 
of heat shock protein (HSP) 90, promoting the polyubiquitylation 
and proteasomal degradation of the pro-growth and prosurvival 
client proteins Bcr-Abl, mutant FLT-3, c-Raf, and AKT in human 
leukemia cells [123]. In a phase I study, LBH589 was administered 
i.v. as a 30-minute infusion on days 1 to 7 of a 21-day cycle. 
LBH589 plasma concentration peaked either at midpoint or at the 
end of the 0.5-hour infusion, then dropped rapidly within the first 4 
hours to reach terminal phase between 4 and 24 hours. The terminal 
half-live ranged from 8 to 16 hours. Intravenous administration of 
LBH589 was usually well tolerated at doses <11.5 mg/m
2 with 
consistent transient antileukemic and biological effects. Potentially 
LBH589-related toxicities included asymptomatic QTcF prolonga-
tion, nausea, diarrhea, vomiting, hypokalemia, loss of appetite and 
thrombocytopenia [124]. 
PXD101 (belinostat) is a novel hydroxamate-type inhibitor of 
histone deacetylase activity that inhibits histone deacetylase activity 
in HeLa cell extracts with an IC50 of 27 nM and induces a concen-
tration-dependent increase in acetylation of histone H4 in tumor cell 
lines. PXD101 is cytotoxic in vitro in a number of tumor cell lines 
with IC50s in the range 0.2–3.4 μM and caused a significant dose-
dependent growth delay in nude mice bearing human ovarian and 
colon tumor xenografts with no significant toxicity [125]. In phase I 
trial conducted in patients with advanced solid tumors, the most 
common adverse events were fatigue, nausea, vomiting, dysgeusia, 
dehydration, anorexia and phlebitis. MTD was 1000 mg/m
2/day, 
while oral bioavailability was 33% [87]. 
Benzamides 
Although structurally diverse, these compounds contain a ben-
zamide moiety and are selective, potent inhibitors of class I 
HDACs. In HDAC enzyme activity assay, the benzamide analogs 
CI994, MS275 and MGCD0103 are partial inhibitors of HeLa nu-
clear extract HDACs activity, as they show full and potent inhibi-
tion of HDAC1 and 3 isoenzymes, but no inhibition of HDAC6 
occurs and high μM concentrations are requested to inhibit HDAC8 
[88] (Table 2).  
MS-275 is an orally available 2-aminophenyl benzamide which 
exerts antiproliferative effects at micromolar levels against a pano-
ply of human tumor cells in vitro, including leukemia cell lines and 
primary leukemia blasts. It has been shown also to induce TGF- 
receptor and trigger the intrinsic pathway of apoptosis [126]. MS-
275 induces the accumulation of reactive oxigen species (ROS) in 
transformed but not normal cells, which was associated with 
upregulation of thioredoxin [94, 97]. MS-275 was shown to syner-
gize with azacitidine to induce cytotoxicity and apoptosis in AML 
and ALL cells [127]. Since the half-life of the oral formulation of 
MS-275 in humans ranges from 39 to 80 hours, once weekly and 
once every-two weeks schedules were used in phase I clinical trials. 
The maximum-tolerated dose was 8 mg/m
2 weekly for 4 weeks 
every 6 weeks. Dose-limiting toxicities included infections and 
neurologic toxicity manifesting as unsteady gait and somnolence. 
Other frequent non-DLTs were fatigue, anorexia, nausea, vomiting, 
hypoalbuminemia, and hypocalcemia [128, 129]. 
CI-994 (4-acetylamino-N-(2'aminophenyl)-benzamide) is a 
substituted benzamide derivative, which has broad antitumor activ-
ity with higher selectivity toward a variety of solid tumor models 
compared to leukemia cell lines. Due to its lack of aqueous solubil-
ity, it requires oral administration. Following CI-994 administra-
tion, inhibition of both histone deacetylation and cellular prolifera-
tion at the G1 to S transition phase of the cell cycle were observed 
[130, 131]. In Phase 1 study conducted in patients with solid tu-
mors, MTD was 8 mg/m
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drug-free interval. Thrombocytopenia was DLT, while other tox-
icities included fatigue and gastrointestinal effects [132]. In a 
pharmacokinetic study on non human primates there was an excel-
lent CSF penetration of CI-994 after i.v. administration [133]. 
MGCD0103 is a novel, orally bioavailable anilide-based 
HDACI developed by MethylGene Inc. in collaboration with Phar-
mion Corporation. This molecule is selective for the class I 
HDACs, and has been shown to inhibit proliferation of a wide vari-
ety of cancer cell lines and to enhance the activity of several differ-
ent chemotherapeutics. After oral administration t1/2 ranges from 7 
to 12 hr, tmax is 0.6-1 hr, and Cmax and AUC increase in a dose-
dependent manner. The inhibition of HDAC activity in whole cells 
extends beyond the plasma half-life of the drug, lasting as long as 
24 hours post drug administration. Two-times and three-times 
weekly schedule were studied in Phase I trials both in solid tumors 
and hematological malignancies [87]. MGCD0103 has been well 
tolerated at doses below 80 mg/m
2/day two times weekly and non-
dose limiting toxicities included fatigue, nausea, diarrhea and vom-
iting [Lancet et al. ASCO2007, Abstract #2516]. No drug-
associated chemistry or hematology toxicities have been observed 
to date. On August 2007, the FDA granted orphan drug designation 
to MGCD0103 for the treatment of Hodgkin's lymphoma. 
Cyclic Peptides 
This class of HDACIs includes both epoxyketone-containing 
and non-epoxyketone-containing tetrapeptides. The most character-
ized drugs belonging to this class is Despipepdide (FK228, Ro-
midepsin), a non-epoxyketone-containing bicyclic tetrapeptide 
HDACI. Depsipeptide is a natural product isolated from Chro-
mobacterium violaceum with antiproliferative activity in a wide 
variety of murine and human tumor cell lines both in vitro and in 
vivo [87]. Depsipeptide is a pro-drug and the active moiety is a 
sulfhydryl group acting as the Zn
+2-chelator. It is a more selective 
inhibitor of the class I HDACs, preferentially blocking HDACs 1 
and 2 versus HDACs 4 and 6 [134] (Table 2). As it is a natural 
product tetrapeptide, depsipeptide is a substrate of MDR-1 and no 
cross-resistance has been observed with other cytotoxic agents [87].  
There have been performed multiple Phases I and II trials with 
depsipeptide, both in solid tumors and in hematological malignan-
cies. After a 4 h i.v. infusion, all the plasma concentration time 
profiles fit a two-compartment model. Generally, it is well tolerated 
with favorable toxicity profile. Common side effects consist of 
fatigue, nausea, vomiting, and transient thrombocytopenia and neu-
tropenia. Several ECG findings have been described during the 
treatment with depsipeptide, including ST and T wave abnormali-
ties, QTc interval prolongation and cardiac arrhythmias. The 
Maximum Tolerated Dose (MTD) was determined to be 17 mg/m
2 
on days 1 and 5 every 21 days. Acetylation of histones in patient’s 
PBMCs was observed confirming inhibition of HDACs by dep-
sipeptide in vivo [135, 136].  
CLINICAL EXPERIENCE  
HDAC Inhibitors 
The clinical activity of HDAC inhibitors alone is very scarce, 
although it has been shown that most of them inhibit histone deace-
tylase activity in vitro, synergizing with all-trans retinoic acid 
(ATRA) in inducing differentiation of myeloid blast cells. Re-
sponses to Valproic Acid monotherapy were observed in 8 out of 18 
patients (44%) with MDS or sAML/MDS, including 1 partial re-
mission [137]. Valproic acid at serum concentrations of 50-100 
μg/ml, combined with ATRA in most of patients, has been used in 
58 patients with AML unfit to receive intensive chemotherapy. 
Response rate was between 5% and 16%, although hematologic 
improvement and stabilization of the disease was observed [138]. 
Similar data were reported on 8 refractory or high-risk AML pa-
tients, where Valproic acid followed by ATRA induced haemato-
logical improvement in 2 patients, while the disease was stable in 5 
and progressive in 1 patient [139].  
The fatty acid sodium phenylbutyrate sodium PB as a continu-
ous i.v. infusion was administered to 23 patients with AML and 
MDS, for 7 consecutive days [108]. Prolonged infusions were well 
tolerated, with only 2 patients on the 21/28 schedule achieving he-
matological improvement.  
A phase 1 trial of orally administered MS-275 was conducted in 
38 adults with advanced acute leukemias [129]. The maximum-
tolerated dose was 8 mg/m
2 weekly for 4 weeks every 6 weeks, 
with DLTs including infections and neurologic toxicity. No re-
sponses by classical criteria were seen.  
Oral vorinostat (SAHA) at doses 100 to 300 mg twice or thrice 
daily for 14 days followed by 1-week rest was used in 41 patients 
with relapsed or refractory leukemias or myelodysplastic syn-
dromes (MDS). Seven patients obtained hematologic improvement, 
including 2 complete responses and 2 complete responses with 
incomplete blood count recovery. Increased histone acetylation was 
observed at all doses and antioxidant gene expression was shown to 
confer vorinostat resistance [140]. 
None of these compounds obtained so far FDA approval for 
treatment of MDS and/or AML, probably because of the low single 
agent activity shown in clinical trials in AML and MDS patients. 
Most expectations for these drugs derive from combination studies 
with hypomethylating agents or other agents with whom synergism 
has been shown in vitro.  
On the other end, vorinostat has been approved for the treat-
ment of peripheral T-cell lymphoma and MGCD0103 for the treat-
ment of relapsed-resistant Hodgkin's lymphoma. 
Azacitidine 
Although hypomethylating agents have existed for about 30 
years, their efficacy has been demonstrated in hematologic malig-
nancies (especially MDS), just in the last 10 years.  
The initial dose-finding Phase I and II studies evaluated 
azacitidine as single agent therapy at 150-200 mg/m
2/d for 5 days in 
children with acute leukaemia (14 AML and 22 ALL). Efficacy was 
high in AML, and the major toxicites reported were nausea, vomit-
ing and diarrhea. Myelotoxicity was also pronounced with nadir of 
white blood cell counts at 10-14 days [141]. Severe and prolonged 
myelosuppression was also observed in 154 adults with AML 
treated at 150-700 mg/m
2/day for 1-7 days, with rather disappoint-
ing clinical responses, ranging from 2 to 15% [142]. Recent trials at 
lower doses and involving more cycles of therapy have shown the 
greatest efficacy. 
The first randomized controlled trial of low-dose azacitidine 
versus supportive care in MDS was published in 2002 and led to the 
FDA approval of the drug. Silverman et al. reported on 191 patients 
with MDS (CALGB 9221 trial), and a low to high IPSS score, ran-
domized to receive azacitidine 75 mg/m
2/day for 7 days, every 4 
weeks, or supportive care [69]. Median times to initial and best 
response were 64 and 93 days, respectively, with 7% complete 
(CR), 16% partial response (PR), and 37% haematological im-
provement (HI) on azacitidine, compared with 5% HI in patients 
receiving supportive care. Among the 65 patients receiving RBC 
transfusions at study entry, 45% had an elimination of all transfu-
sions and another 9% had a reduction in transfusions by 50%. In 
addition, lineage responses for platelets and WBC occurred in 47% 
and 40% of patients treated with azacitidine. Responses were ob-
served in both low/int-1 as well as int-2/high IPSS score patients 
and they were associated to longer median time to leukemic trans-
formation or death (21 months for azacitidine versus 13 months for 
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were significantly improved in patients on azacitidine, especially 
fatigue and psychological state [141].  
After the publication in 2000 of the WHO classification [144], 
MDS with 20-30% of blasts were re-classified as AML. Accord-
ingly, 268 patients treated using azacitidine at 75mg/m
2/day for 7 
days on the CALGB 9221 trial and on 2 previous protocols 
(CALGB 8421, intravenous infusion and 8921, subcutaneous) were 
re-analyzed, according also to the IWG response criteria [145]. 
Response rates were similar in the 3 trials: a median of 3 cycles 
were required for response, with 90% of patients achieving re-
sponse by cycle 6. Myelosuppression was a major issue, with 15 
days for haemoglobin nadir value, 16 days for platelets and white 
blood cells and 17 days for neutrophils, but surprisingly there was 
no increase in the rate of bleeding or infections. Using WHO crite-
ria, 27 AML patients received azacitidine versus 25 patients as-
signed to observation: 7-16% achieved CR or PR, while 23-32% 
had HI. Response lasted a median of 7.3 months.  
Twenty patients with AML were enrolled in a compassionate 
azacitidine program between 1996 and 2001 [146]. CR and PR 
were observed in 20% and 25% of patients, and HI in 15% of pa-
tients. Median survival of responders was 15 months, versus 2.5 
months for non-responders. Most common toxic effects were febrile 
neutropenia and pneumonia (6 patients), and 3 patients died due to 
infection. 
In summary, the standard azacitidine doses of 75 mg/m
2/day for 
7 days every 4 weeks, leads to 10-20% CR and PR rates in MDS 
and AML patients. Treatment is associated with myelosuppression 
but it results into transfusion independency and prolonged survival 
in most of the patients. These data have been confirmed by a Phase 
III, international, multicenter, randomized, prospective trial which 
included 358 patients with higher-risk MDS patients, FAB-defined 
as RAEB, RAEB-T, or CMML (10-29% marrow blasts) with an 
IPSS of Int-2 or High [Fenaux et al. ASH 2007, Abstract #817]. 
This study demonstrated the superiority of azacitidine over three 
conventional care regimens (CCR; best supportive care, low-dose 
cytarabine, standard chemotherapy), with a median overall survival 
of 24.4 months for azacitidine and 15 months for the three CCR. 
Still, the optimal administration schedule and the possibility to 
deliver azacitidine on an outpatient basis is an issue. A phase II, 
multicenter trial [Lyons et al. ASH 2007, Abstract #819] is ongoing 
in MDS, randomizing patients to either azacitidine 75 mg/m
2/day 5-
2-2 (5 days, followed by 2 days stop, and 2 days treatment), 
azacitidine 50 mg/m
2/day 5-2-5 (5 days, 2 days stop and 5 days 
treatment) or azacitidine 75 mg/m
2/day 5 [for 5 days]. After 6 cy-
cles of azacitidine, patients meeting International Working Group 
MDS response/improvement criteria defined as CR, PR, stable 
disease (SD), or HI were eligible to receive an additional 12 cycles. 
Of 139 randomized patients who had received at least 2 cycles of 
treatment, HI occurred in 51% of them, with red blood cell transfu-
sion independence. Similar percentages of responses were observed 
in all 3 alternative azacitidine dosing schedules, with similar safety 
and efficacy to the FDA-approved regimen. 
Azacitidine Combination Studies 
Given the characteristic hypomethylating activity of azacitidine, 
one of the most attractive combinations is with hystone deacetylase 
inhibitors. Maslak et al. reported on 10 patients (8 AML, two MDS) 
treated with 7 consecutive daily subcutaneous (s.c.) injections of 
azacitidine at 75mg/m
2 followed by 5 days of sodium phenylbu-
tyrate given intravenously (i.v.) at a dose of 200 mg/kg [147]. None 
of the patients achieved CR, 3 patients achieve PR (2 AML, 1 
CMML-2) and 2 other patients had SD; 4 of 5 patients received 
multiple cycles of this combination. Side effects were mild, but 
frequent, with over 50% of patients presenting an injection site 
reaction, somnolence/fatigue, nausea and vomiting. No change in 
the acetylated forms of histones H3 and H4 were observed follow-
ing therapy with azacitidine, while, as expected, levels of acetylated 
histones, in particular H4, increased following phenylbutyrate in 
patients’ peripheral blood and/or bone marrow mononuclear cells.  
The synergistic antileukemia activity of azacitidine and the his-
tone deacetylase inhibitor valproic acid, in the attempt to restore 
sensitivity to the differentiating effect of all-trans retinoic acid 
(ATRA) was tested in 49 AML and 4 MDS patients of a median 
age of 69 years [148]. Patients had refractory or relapsed AML 
(n=19) or high-risk MDS (n=1), while 33 elderly patients (30 AML, 
3 MDS), who refused or were not candidates for chemotherapy, 
were treated front-line. Three dose levels of valproic acid (50, 62.5 
and 75 mg/kg orally days 1-7) were explored, in combination with 
azacitidine (75 mg/m2 sc, days 1-7) and ATRA (45 mg/m
2 orally, 
days 3-7 of azacitidine and valproic acid). Median number of 
courses to first response was 1 (range 1-3), mostly at the valproic 
acid dose of 50 mg/kg. Cytogenetic response was observed in 36% 
of patients, CR and CRp occurred in 12 and 3 patients, BM re-
sponse in 7 patients, with an overall response rate of 42%. Signifi-
cantly higher response rates were observed in patients reaching 
higher valproic acid plasma levels. 
Decitabine 
In the recent years several studies have been reported using the 
analogue compound, decitabine. In a phase I study, 48 patients (35 
AML, 7 MDS, 1 ALL, 5 CML), mostly with unfavourable karyo-
type, were treated with low-dose prolonged exposure to decitabine 
[149]. Dose ranged between 50 and 300 mg/m
2 per course, with 
decitabine at 5, 10, 15, or 20 mg/m
2 i.v. over one hour daily, 5 
days/week for 2 consecutive weeks or 15 mg/m
2 daily for 15 or 20 
days. Side effects were tolerable: grade 3 liver dysfunction was 
observed in 6 patients, febrile episodes were observed in 52% of 
patients. The best dose schedule was 15 mg/m
2 daily for 10 days, 
with a response rate of 83% (4 CR, 1 PR). Higher doses were not 
associated with increased response rates. 
Wijermans et al. [78] summarized the results of 177 patients 
with MDS (23 RA/RARS, 66 RAEB, 65 RAEB-t, 23 CMML), 
treated in 3 phase II studies. The dose was 40-75 mg/m
2 continuous 
infusion in study PCH 91-1 (n=29 patients), while in the PCH 95-
11 and PCH 97-19 studies a fixed dose of 15 mg/m
2 every 8 hours 
(45 mg/m
2/d) was given as 3-4-h infusion, 3 days every 6 weeks 
(median 4 cycles). CR and PR rates were 24% and 10%, HI was 
observed in 14% of patients, while 18% had progressive disease 
and there were 12 toxic deaths. Survival was longer in younger 
patients, with IPSS Int-1 and low risk cytogenetics. 
In the U.S., 170 patients with MDS were randomized to receive 
decitabine at a dose of 15 mg/m
2 i.v. over 3 hours every 8 hours for 
3 days every 6 weeks, or best supportive care [150]. Patients treated 
with decitabine achieved a 17% overall response rate, including 9% 
complete responses, while HI was obtained in 13% of patients. 
Responses lasted for a median of 10.3 months and were associated 
with transfusion independence. Patients treated with decitabine had 
a trend toward a longer median time to progression to AML or 
death (12.1 vs. 7.8 months in the supportive care arm).  
Matching patients treated with the 135 mg/m
2 Decitabine 
schedule to a hystorical control group of 115 patients with MDS, of 
similar age, karyotype and an IPSS score Intermediate-1 to High, 
treated with intensive chemotherapy showed lower early mortality 
and improved overall survival (22 versus 12 months) for decitabine 
treatment [151]. In these patients, independent predictors for 
achieving IWG CR were chronic myelomonocytic leukaemia 
(CMML) vs MDS, shorter duration of MDS, and no prior MDS 
therapy, especially when combined. 
Similar to azacitidine, the optimal decitabine schedule has not 
been defined yet. Kantarjian et al. randomized 77 patients with 
MDS and 17 with CMML to 3 different decitabine schedules: 20 1284    Current Medicinal Chemistry,  2008 Vol. 15, No. 13  Leone et al. 
mg/m
2/day i.v. for 5 days, versus 20 mg/m
2/day s.c. for 5 days, 
versus 10 mg/m
2/day i.v. for 10 days. The highest CR rates (39%) 
and improved epigenetic p15 reactivation were obtained using the 5 
day i.v. schedule [79]. 
One of the major issue is whether hypomethylating treatment 
should be lifetime, or whether it can be interrupted once response 
has been achieved. At present, tendency is towards continous main-
teinance treatment. The efficacy of retreatment has been shown by 
Ruter et al. who reported on 22 patients with MDS treated with a 
median of 6 cycles low-dose decitabine, who received decitabine as 
retreatment at the time of disease recurrence. Retreatment was initi-
ated 11 months after the last course of decitabine: 10 patients (45%) 
responded (1 CR, 2 PR, 7 HI), while 12 patients did not respond. 
Second responders to decitabine retreatment were found less fre-
quently in the high-risk IPSS group, compared to non-responders 
[152]. 
Decitabine Combination Studies 
Decitabine was combined to valproic acid in 48 patients with 
AML and 6 MDS [153]. Decitabine was used at a fixed dose of 15 
mg/m
2 i.v., daily for 10 days, concomitantly with escalating doses 
of valproic acid orally for 10 days. Ten patients obtained CR and 2 
CRp, with a median survival of 15.3 months in responders and 4.9 
months in nonresponders. Median remission duration was 7.2 
months. The 50 mg/kg daily dose of valproic acid was found to be 
safe and was associated to higher response rate. Transient DNA 
hypomethylation and global histone H3 and H4 acetylation were 
induced, and were associated with p15 reactivation. Surprisingly, 
patients with lower pretreatment levels of p15 methylation had a 
significantly higher response rate. 
To determine an optimal biologic dose (OBD) of decitabine as 
single agent and then the maximum-tolerated dose (MTD) of val-
proic acid combined with decitabine, 25 patients with AML (13 
untreated, 13 relapsed) of a median age of 70 years were treated in 
a phase I trial [154]. Fourteen patients received decitabine alone 
and the OBD was 20 mg/m
2/day i.v. for 10 days. Eleven patients 
received decitabine 20 mg/m
2/day for 10 days plus dose-escalating 
valproic acid (days 5-21). Of 21 assessable patients, 11 (52%) re-
sponded: 4 with morphologic and cytogenetic CR; 4 with incom-
plete CR, and three with PR. In untreated AML, 4 of 9 assessable 
patients achieved CR. Clinical responses appeared similar for decit-
abine alone or with valproic acid. Dose-limiting encephalopathy 
occurred in 2 of 2 patients at valproic acid 25 mg/kg/day and 1 of 6 
patients at 20 mg/kg/day dose. 
Low-dose decitabine (5 mg/m
2/day i.v., 5 days/week for 2 
weeks) was combined to 600 mg/day imatinib in a phase II study in 
patients with CML in accelerated and myeloid blastic phase [155]. 
After 91 cycles in 28 patients (25 with imatinib resistance; 18 in 
accelerated, 10 in blastic phase), CR were observed in 9 (32%), PR 
in 1 (4%), and HI in 2 (7%) patients. Major and minor cytogenetic 
responses were observed in 5 (18%) and 3 (11%) patients. The 
hematologic response rate was higher in patients without BCR-
ABL kinase mutations (10 of 19) than in those with mutations (1 of 
7). Median duration of hematologic response was 18 weeks, with 
myelosuppression as the major adverse effect resulting in neutro-
penic fever in 9 patients (32%). 
Prognostic Factors Associated with Outcome 
Although CR rates in AML and MDS range between 10-20%, 
the major advantages of epigenetic therapy is hematologic im-
provement, transfusion independency, and delayed transformation 
into AML, which results into prolonged survival, especially in 
MDS patients. Since this is a biologic approach, it remains to define 
which are the molecular factors associated to best responses, to 
identify patients who may best profit from treatment. Several stud-
ies have shown reactivation of silenced genes after hypomethylat-
ing therapy in vitro, but this effect is still matter of debate in vivo.  
Gore et al. demonstrated a significant decrease of p15 methyla-
tion in MDS and AML patients treated with low-dose azacitidine 
and the histone deacetylase inhibitor sodium phenylbutyrate. Re-
expression of p15 protein was increased and correlated with clinical 
response. Surprisingly, azacitidine alone was sufficient to increase 
the overall acetylation level of histones H3 and H4, which was 
further increased upon phenylbutyrate treatment [156]. 
Using azacitidine and valproic acid, Soriano et al. showed using 
a bisulfite pyrosequencing assay, that global DNA methylation, was 
not associated to response, but significantly decreased by day 7, and 
returned towards baseline by day 0 of the next cycle [148]. Al-
though a modest but significant increment on p15 and p21 mRNA 
expression was detected, this was not associated with clinical re-
sponse. Similarly, valproic acid dose level and histone acetylation 
did not correlate to response.  
In the same way, bisulphite genomic sequencing of the p15 
promoter showed 12.2% pre-treatment methylation in 14 of 17 
patients treated with Azacitidine. p15 methylation was reduced by 
6.8% in 8 of 17 patients, but this did not correlate with response. 
Significantly lower baseline methylation occurred in responders 
(9.8% versus 16.2% in non-responders), while hypermethylation 
over 24% and absent p15 mRNA expression were associated to lack 
of response. Cell death with reduced bone marrow cellularity and 
increased apoptosis, rather than p15 demethylation better correlated 
with response [44]. 
These data show that since hypomethylation is induced both in 
normal and neoplastic cells, the analysis of global methylation dy-
namics could be considered as a marker of the biological activity of 
the drug, but it is not necessarily related to clinical activity. Specific 
gene methylation studies, other than p15, may identify more reli-
able markers of response. Accordingly, in patients treated with 
decitabine and valproic acid, drug-induced re-expression of estro-
gen receptor was associated with clinical response [154]. ER pro-
moter demethylation, global DNA hypomethylation, depletion of 
DNA methyltransferase enzyme, and histone hyperacetylation were 
also observed.  
It is also possible that the clinical activities of both azacitidine 
and valproic acid are only partially related to the inhibition of DNA 
methylation and of hystone deacetylation, and that other mecha-
nisms may be prevalent.  
Cytogenetic abnormalities including complex karyotype and 
chromosome 7 anomalies have been associated to increased re-
sponse rates to hypomethylating therapy. Of 34 patients with MDS 
or AML, treated with azacitidine, 5 of 7 complete responders had 
chromosome 7 abnormalities [44]. On the contrary, Kantarjian et al. 
showed that independent adverse prognostic factors for survival for 
115 patients with high-risk MDS were chromosome 5 and/or 7 
abnormalities, older age, and prior MDS therapy (excluding growth 
factors) [157]. The National Cancer Research Institute trial AML14 
comparing low-dose cytarabine and hydroxyurea showed no benefit 
for patients with MDS and AML and adverse cytogenetics [158].  
When looking at morphology, patients with CMML were re-
ported to have increased reponse rates. decitabine at 100 mg/m
2 per 
course every 4 weeks was administered for a median of 9 courses to 
19 adults with CMML. Eleven patients (58%) achieved CR and 2 
had HI, for an overall response rate of 69% according to the modi-
fied IWG criteria [159].  
CONCLUDING REMARKS AND FUTURE DIRECTIONS  
Azacitidine and decitabine, two cytidine analogues, were the 
first demethylating agents entered in clinical trials. First used at 
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demethylating agents gave definetively more satisfying results 
when used at low dose schedule for the treatment of MDS. When 
compared to supportive care, Azacitidine and Decitabine showed 
high overall response rate, reduced transfusion requirement, im-
proved quality of life and reduced risk of leukemic transformation 
in MDS patients. In particular, Azacitidine significantly prolonged 
survival in MDS patients when compared to conventional care 
regimens in the AZA-001 Phase III randomized prospective trial 
[Fenaux et al. ASH 2007, Abstract #817], while a survival advan-
tage was described for decitabine over intensive chemotherapy in 
high risk MDS patients compared with matched historical controls 
[160]. A molecular biomarker of responsivity to demethylating 
treatment has still to be identified, since no stable correlation has 
been observed between response to azanucleotides and promoter 
methylation of single genes, as p15. New oral DNMT inhibitors, as 
oral azacitidine and zebularine, are under investigation. 
Valproic acid and Sodium phenylbutirrate, the first HDAC in-
hibitors studied, induce terminal differentiation of leukemic blasts 
in vitro and showed scarce activity when used as single agents in 
vivo. Since these drugs were shown to synergize with DNMTs in-
hibitors in inducing re-expression of silenced gene, combination 
studies with both inhibitors are undergoing, although it is not clear 
yet whether HDAC inhibitors add to the efficacy of hypomethylat-
ing agents. New more effective and well tolerated HDAC inhibi-
tors, including depsipeptide, SAHA, LBH589, PDX101, MS-275, 
CI-994 and MGCD0103, entered in clinical trials alone or in com-
bination. These compounds will hopefully hold in vivo the premises 
of the epigenetic reactivation often reported in vitro, with a more 
acceptable toxicity profile. 
ACKNOWLEDGEMENTS 
This work was supported by grants from M.I.U.R. (Ministero 
dell’ Università e della Ricerca) and A.I.R.C. (Associazione Italiana 
per la Ricerca sul Cancro). 
REFERENCES 
[1]  Jones, P.A.; Baylin, S.B. Cell, 2007, 128, 683. 
[2]  Lanzuolo, C.; Orlando, V. Cell. Mol. Life Sci., 2007, 64, 1043. 
[3]  Kouzarides, T. Cell, 2007, 131, 822. 
[4]  Egger, G.; Liang, G.; Aparicio, A.; Jones, P.A. Nature, 2004, 429, 457. 
[5]  Laird, P.W. Hum. Mol. Genet., 2005, 14, R65. 
[6]  Jones, P.A.; Baylin, S.B. Nat. Rev. Genet., 2002, 3, 415. 
[7]  Galm, O.; Herman, J.G.; Baylin, S.B. Blood Rev., 2006, 20, 1. 
[8]  Esteller, M.; Herman, J.G. J. Pathol., 2002, 196, 1. 
[9]  Herman, J.G.; Baylin, S.B. N. Engl. J. Med., 2003, 349, 2042. 
[10]  Bird, A. Genes Dev., 2002, 16, 6. 
[11]  Holliday, R.; Grigg, G.W. Mutat. Res., 1993, 285, 61. 
[12]  Bestor, T.H. Gene, 1988, 74, 9. 
[13]  Okano, M.; Bell, D.W.; Haber, D.A.; Li, E. Cell, 1999, 9, 9247. 
[14]  Weber, M.; Hellmann, I.; Stadler, M.B.; Ramos, L.; Pääbo, S.; Rebhan, M.; 
Schübeler, D. Nat. Genet., 2007, 39, 457.  
[15]  Feinberg, A.P.; Vogelstein, B. Nature, 1983, 301, 89. 
[16]  Feinberg, A.P. Cancer Res., 1999, 59, 1743s.  
[17]  Eden, A.; Gaudet, F.; Waghmare, A.; Jaenisch, R. Science, 2003, 300, 455  
[18]  Klose, R.J.; Bird, A.P. Trends Biochem. Sci., 2006, 31, 89. 
[19]  Zhang, Y.; Ng, H.H.; Erdjument-Bromage, H.; Tempst, P.; Bird, A.; Rein-
berg, D. Genes Dev., 1999, 13, 1924.  
[20]  Santoro, R.; Li, J.; Grummt, I. Nat. Genet., 2002, 32, 393.  
[21]  Yoon, H.G.; Chan, D.W.; Reynolds, A.B.; Qin, J.; Wong, J. Mol. Cell, 2003, 
12, 723.  
[22]  Nan, X.; Ng, H.H.; Johnson, C.A.; Laherty, C.D.; Turner, B.M.; Eisenman, 
R.N.; Bird, A. Nature, 1998, 393, 386. 
[23]  Jones, P.L.; Veenstra, G.J.; Wade, P.A.; Vermaak, D.; Kass, S.U.; Lands-
berger, N.; Strouboulis, J.; Wolffe, A.P. Nat. Genet., 1998, 19, 187.  
[24]  Turner, B.M. Nat. Cell Biol., 2007, 9, 2. 
[25]  Sterner, D.E.; Berger, S.L. Microbiol. Mol. Biol. Rev., 2000, 64, 435.  
[26]  Yang, X.J. Nucleic Acids Res., 2004, 32, 959. 
[27]  Roth, S.Y.; Denu, J.M.; Allis, C.D. Annu. Rev. Biochem., 2001, 70, 81. 
[28]  Struhl, K. Genes Dev., 1998, 12, 599. 
[29]  Fuks, F.; Burgers, W.A.; Brehm, A.; Hughes-Davies, L.; Kouzarides, T. Nat. 
Genet., 2000, 24, 88. 
[30]  Rountree, M.R.; Bachman, K.E.; Herman, J.G.; Baylin, S.B. Oncogene, 
2001, 20, 3156. 
[31]  Minucci, S.; Pelicci, P.G. Nat. Rev. Cancer, 2006, 6, 38.  
[32]  Jenuwein, T.; Allis, C.D. Science, 2001, 293, 1074. 
[33]  Seligson, D.B.; Horvath, S.; Shi, T.; Yu, H.; Tze, S.; Grunstein, M.; Kurdis-
tani, S.K. Nature, 2005, 435, 1262.  
[34]  Fraga, M.F.; Ballestar, E.; Villar-Garea, A.; Boix-Chornet, M.; Espada, J.; 
Scotta, G.; Bonaldi, T.; Haydon, C.; Ropero, S.; Petrie, K.; Iyer, N.G.; Pérez-
Rosado, A.; Calvo, E.; Lopez, J.A.; Cano, A.; Calasanz, M.J.; Colomer, D.; 
Piris, M.A.; Ahn, N.; Imhof, A.; Caldas, C.; Jenuwein, T.; Esteller, M. Nat. 
Genet., 2005, 37, 391. 
[35]  Esteller M. Nat. Rev. Genet., 2007, 8, 286. 
[36]  Knudson, A.G. J. Cancer Res. Clin. Oncol., 1996, 122, 135. 
[37]  Zardo, G.; Tiirikainen, M.I.; Hong, C.; Misra, A.; Feuerstein, B.G.; Volik, S.; 
Collins, C.C.; Lamborn, K.R.; Bollen, A.; Pinkel, D.; Albertson, D.G.; Cos-
tello, J.F. Nat. Genet., 2002, 32, 453.  
[38]  Redner, R.L.; Wang, J.; Liu, J.M. Blood, 1999, 94, 417. 
[39]  Bhalla, K.N. J. Clin. Oncol., 2000, 23, 3971. 
[40]  Liu, T.X.; Becker, M.W.; Jelinek, J.; Wu, W.S.; Deng, M.; Mikhalkevich, N.; 
Hsu, K.; Bloomfield, C.D.; Stone, R.M.; DeAngelo, D.J.; Galinsky, I.A.; Is-
sa, J.P.; Clarke, M.F.; Look, A.T. Nat. Med., 2007, 13, 78. 
[41]  Fazi, F.; Racanicchi, S.; Zardo, G.; Starnes, L.M.; Mancini, M.; Travaglini, 
L.; Diverio, D.; Ammatuna, E.; Cimino, G.; Lo-Coco, F.; Grignani, F.; 
Nervi, C. Cancer Cell., 2007, 12, 457. 
[42]  Länger, F.; Dingemann, J.; Kreipe, H.; Lehmann, U. Leuk. Res., 2005, 29, 
325. 
[43]  Lübbert, M. Leukemia, 2003, 17, 1762. 
[44]  Raj, K.; John, A.; Ho, A.; Chronis, C.; Khan, S.; Samuel, J.; Pomplun, S.; 
Thomas, N.S.; Mufti, G.J. Leukemia, 2007, 21, 1937. 
[45]  Christiansen, D.H.; Andersen, M.K.; Pedersen-Bjergaard, J. Leukemia, 2003, 
17, 1813. 
[46]  Agrawal, S.; Unterberg, M.; Koschmieder, S.; zur Stadt, U.; Brunnberg, U.; 
Verbeek, W.; Büchner, T.; Berdel, W.E.; Serve, H.; Müller-Tidow, C. Can-
cer Res., 2007, 67, 1370. 
[47]  Aggerholm, A.; Holm, M.S.; Guldberg, P.; Olesen, L.H.; Hokland, P. Eur. J. 
Haematol., 2006, 76, 23.  
[48]  Claus, R.; Lübbert, M. Oncogene, 2003, 22, 6489. 
[49]  Chim, C.S.; Liang, R.; Kwong, Y.L. Hematol. Oncol., 2002, 20, 167. 
[50]  Piimi, J.; orm, F. Collection Czech. Chem. Commun., 1964, 29, 2576. 
[51]  Pískala, A.; orm, F. Collection Czech. Chem. Commun., 1965, 30, 2801. 
[52]  Jones, P.A.; Taylor, S.M.; Wilson, V.L. Recent Results Cancer Res., 1983, 
84, 202. 
[53]  Christman, J.K.; Mendelsohn, N.; Herzog, D.; Scneiderman, N. Cancer Res., 
1983, 43, 763. 
[54]  Pinto, A.; Attadia, V.; Fusco, A.; Ferrara, F.; Spada, O.A.; Di Fiore, P.P. 
Blood, 1984, 64, 922. 
[55]  Glover, A.B.; Leyland-Jones, B. Cancer Treat. Rep., 1987, 71, 959. 
[56]  Chuang, J.C.; Yoo, C.B.; Kwan, J.M.; Li, T.W.H.; Liang, G.; Yang, A.S.; 
Jones, P.A. Mol. Cancer Ther., 2005, 4, 1515. 
[57]  Momparler, R.L.; Derse, D. Biochem. Pharmacol., 1979, 28, 1443.  
[58]  Ghoshal, K.; Datta, J.; Majumder, S.; Bai, S.; Kutay, H.; Motiwala, T.; 
Jacob, S.T. Mol. Cell. Biol., 2005, 25, 4727.  
[59]  Christman, J.K. Oncogene, 2002, 21, 5483. 
[60]  Ayyoub, M.; Taub, R.N.; Keohan, M.L.; Hesdorffer, M.; Metthez, G.; Me-
meo, L.; Mansukhani, M.; Hibshoosh, H.; Hesdorffer, C.S.; Valmori, D. 
Cancer Immun., 2004, 4, 7. 
[61]  Chan, A.T.; Tao, Q.; Robertson, K.D.; Flinn, I.W.; Mann, R.B.; Klencke, B.; 
Kwan, W.H.; Leung, T.W.; Johnson, P.J.; Ambinder, R.F. J. Clin. Oncol., 
2004, 22, 1373. 
[62]  Murakami, T.; Li, X.; Gong, J.; Bhatia, U.; Traganos, F.; Darzynkiewicz, Z. 
Cancer Res., 1995, 55, 3093. 
[63]  Chabot, G.; Bouchard, J.; Momparler, R.L. Biochem. Pharmacol., 1983, 32, 
1327. 
[64]  Marquez, V.E.; Kelley, J.A.; Agraria, R.; Ben-Kasus, T.; Cheng, J.C.; Yoo, 
C.B.; Jones, P.A. Ann. N. Y. Acad. Sci., 2005, 1058, 246.  
[65]  Lemaire, M.; Momparler, L.F.; Bernstein, M.L.; Marquez, V.E.; Momparler, 
R.L. Anticancer Drugs, 2005, 16, 301. 
[66]  Stewart, D.J.; Donehower, R.C.; Eisenhauer, E.A.; Wainman, N.; Shah, 
A.K.; Bonfils, C. ; MacLeod, A.R.; Besterman, J.M.; Reid, G.K. Ann. On-
col., 2003, 14, 766.  
[67]  Winquist, E.; Knox, J.; Ayoub, J.P.; Wood, L.; Wainman, N.; Reid, G.K.; 
Pearce, L.; Shah, A.; Eisenhauer, E. Invest. New Drugs, 2006, 24, 159. 
[68]  Kaminskas, E.; Farrell, A.T.; Wang, Y.C.; Sridhara, R.; Pazdur, R. Oncolo-
gist, 2005, 10, 176. 
[69]  Silverman, L.R.; Demakos, E.P.; Peterson, B.L.; Kornblith, A.B.; Holland, 
J.C.; Odchimar-Reissig, R.; Stone, R.M.; Nelson, D.; Powell, B.L.; DeCas-
tro, C.M.; Ellerton, J.; Larson, R.A.; Schiffer, C.A.; Holland, J.F. J. Clin. 
Oncol., 2002, 20, 2429. 
[70]  Gaudet, F.; Hodgson, J.G.; Eden, A.; Jackson-Grusby, L.; Dausman, J.; Gray, 
J.W.; Leonhardt, H.; Jaenisch, R. Science, 2003, 300, 489. 
[71]  Rosen, M.B.; House, H.S.; Francis, B.M.; Chernoff, N. J. Toxicol. Environ. 
Health, 1990, 29, 201. 
[72]  Doiron, K.M.; Lavigne-Nicolas, J.; Cupples, C.G. Mutat. Res., 1999, 429, 37. 
[73]  Carr, B.I.; Reilly, J.G.; Smith, S.S.; Winberg, C.; Riggs, A. Carcinogenesis, 
1984, 5, 1583. 
[74]  Momparler, R.L. Semin. Hematol., 2005, 42, S9. 
[75]  Chabot, G.; Momparler, R.L. Cancer Res., 1983, 43, 592. 1286    Current Medicinal Chemistry,  2008 Vol. 15, No. 13  Leone et al. 
[76]  Rivard, G.E.; Momparler, R.L.; Demers, J.; Benoit, P.; Raymond, R.; Lin, 
K.; Momparler, L.F. Leuk. Res., 1981, 5, 453. 
[77]  Wijermans, P.; Lübbert, M.; Verhoef, G.; Bosly, A.; Ravoet, C.; Andre, M.; 
Ferrant, A. J. Clin. Oncol., 2000, 18, 956. 
[78]  Wijermans, P.W.; Lübbert, M.; Verhoef, G.; Klimek, V.; Bosly, A. Ann. 
Hematol., 2005, 84, 9. 
[79]  Kantarjian, H.; Oki, Y.; Garcia-Manero, G.; Huang, X.; O'Brien, S.; Cortes, 
J.; Faderl, S.; Bueso-Ramos, C.; Ravandi, F.; Estrov, Z.; Ferrajoli, A.; Wier-
da, W.; Shan, J.; Davis, J.; Giles, F.; Saba, H.I.; Issa, J.P. Blood, 2007, 109, 
52.  
[80]  Cashen, A.F.; Shah, A.K.; Todt, L.; Fisher, N.; Dipersio, J. Cancer Chemo-
ther. Pharmacol., 2008, 61, 759. 
[81]  Snyder, R.D.; Lachmann, P.J. Mutat. Res., 1989, 226, 185. 
[82]  Ji, W.; Hernandez, R.; Zhang, X.Y.; Qu, G.Z.; Frady, A.; Varela, M.; Ehr-
lich, M. Mutat. Res., 1997, 379, 33. 
[83]  Samlowski, W.E.; Leachman, S.A.; Wade, M.; Cassidy, P.; Porter-Gill, P.; 
Busby, L.; Wheeler, R.; Boucher, K.; Fitzpatrick, F.; Jones, D.A.; Karpf, 
A.R. J. Clin. Oncol., 2005, 23, 3897. 
[84]  Laird, P.W.; Jackson-Grusby, L.; Fazeli, A. Cell, 1995, 81, 197 
[85]  Yoshida, M.; Kijima, M.; Akita, M.; Beppu, T. J. Biol. Chem., 1990, 265, 
17174. 
[86]  Kijima, M.; Yoshida, M.; Sugita, K.; Horinouchi, S.; Beppu, T. J. Biol. 
Chem., 1993, 268, 22429. 
[87]  Glaser, K.B. Biochem. Pharmacol., 2007, 74, 659. 
[88]  Beckers, T.; Burkhardt, C.; Wieland, H.; Gimmnich, P.; Ciossek, T.; Maier, 
T.; Sanders, K. Int. J. Cancer, 2007, 121, 1138.  
[89]  Miller, T. A.; Witter, D. J.; Belvedere, S. J. Med. Chem., 2003, 46, 5097. 
[90]  Mai, A.; Massa, S.; Rotili, D.; Cerbara, I.; Valente, S.; Pezzi, R.; Simeoni, S.; 
Ragno, R. Med. Res. Rev., 2005, 25, 261. 
[91]  Glaser, K.B.; Staver, M.J.; Waring, J.F.; Stender, J.; Ulrich, R.G.; Davidsen, 
S.K. Mol. Cancer Ther., 2003, 2, 151. 
[92]  Mitsiades, C.S.; Mitsiades, N.S.; McMullan, C.J.; Poulaki, V.; Shringarpure, 
R., Hideshima, T.; Akiyama, M.; Chauhan, D.; Munshi, N.; Gu, X.; Bailey, 
C.; Joseph, M.; Libermann, T.A.; Richon, V.M.; Marks, P.A.; Anderson, 
K.C. Proc. Natl. Acad. Sci. USA, 2004, 101, 540. 
[93]  Peart, M.J.; Smyth, G.K.; van Laar, R.K.; Bowtell, D.D.; Richon, V.M.; 
Marks, P.A.; Holloway, A.J.; Johnstone, R.W. Proc. Natl. Acad. Sci. USA, 
2005, 102, 3697. 
[94]  Ungerstedt, J.S.; Sowa, Y.; Xu, W.S.; Shao, Y.; Dokmanovic, M.; Perez, G.; 
Ngo, L.; Holmgren, A.; Jiang, X.; Marks, P.A. Proc. Natl. Acad. Sci. USA, 
2005, 102, 673.  
[95]  Richon, V.M.; Sandhoff, T.W.; Rifkind, R.A.; Marks, P.A. Proc. Natl. Acad. 
Sci. USA, 2000, 97, 10014. 
[96]  Gui, C.Y.; Ngo, L.; Xu, W.S.; Richon, V.M.; Marks, P.A. Proc. Natl. Acad. 
Sci. USA, 2004, 101, 1241.  
[97]  Rosato, R.R.; Almenara, J.A.; Grant, S. Cancer Res., 2003, 63, 3637. 
[98]  Shao, Y.; Gao, Z.; Marks, P.A.; Jiang, X. Proc. Natl. Acad. Sci. USA, 2004, 
101, 18030. 
[99]  Cohen, H.Y.; Lavu, S.; Bitterman K.J.; Hekking, B.; Imahiyerobo, T.A.; 
Miller, C.; Frye, R.; Ploegh, H.; Kessler, B.M.; Sinclair, D.A. Mol. Cell., 
2004, 13, 627. 
[100]  Subramanian, C.; Opipari, A.W.Jr.; Bian, X.; Castle, V.P.; Kwok, R.P. Proc. 
Natl. Acad. Sci. USA, 2005, 102, 4842. 
[101]  Munshi, A.; Kurland, J.F.; Nishikawa, T.; Tanaka, T.; Hobbs, M.L.; Tucker, 
S.L.; Ismail, S.; Stevens, C.; Meyn, R.E. Clin. Cancer Res., 2005, 11, 4912. 
[102]  Camphausen, K.; Tofilon, P.J. J. Clin. Oncol., 2007, 25, 4051. 
[103]  Gurvich, N.; Tsygankova, O.M.; Meinkoth, J.L.; Klein, P.S. Cancer Res., 
2004, 64, 1079. 
[104]  Miller, A.A.; Kurschel, E.; Osieka, R.; Schmidt, C.G. Eur. J. Med. Chem., 
1987, 23, 1283. 
[105]  Dover, G.J.; Brusilow, S.; Samid, D. N. Engl. J. Med., 1992, 327, 569. 
[106]  DiGiuseppe, J.A.; Weng, L.J.; Yu, K.H.; Fu, S.; Kastan, M.B.; Samid, D.; 
Gore, S.D. Leukemia, 1999, 13, 1243. 
[107]  Comte, B.; Kasumov, T.; Pierce, B.A.; Puchowicz, M.A.; Scott, M.E.; 
Dahms, W.; Kerr, D.; Nissim, I.; Brunengraber, H. J. Mass. Spectrom., 2002, 
37, 581. 
[108]  Gore, S.D.; Weng, L.J.; Figg, W.D.; Zhai, S.; Donehower, R.C.; Dover, G.; 
Grever, M.; Griffin, C.A.; Grochow, L.B.; Rowinsky, E.K.; Zabalena, Y.; 
Hawkins, A.L.; Burks, K.; Miller, C.B. Clin. Cancer Res., 2002, 8, 963. 
[109]  Gore, S.D.; Weng, L.J.; Zhai, S.; Figg, W.D.; Donehower, R.C.; Dover, G.J.; 
Grever, M.; Griffin, C.A.; Grochow, L.B.; Rowinsky, E.K.; Zabalena, Y.; 
Hawkins, A.L.; Burks, K.; Miller, C.B. Clin. Cancer Res., 2001, 7, 2330. 
[110]  Aviram, A.; Zimrah, Y.; Shaklai, M.; Nudelman, A.; Rephaeli, A. Int. J. 
Cancer, 1994, 56, 906. 
[111]  Batova, A.; Shao, L.E.; Diccianni, M.B.; Yu A.L.; Tanaka, T.; Rephaeli, A.; 
Nudelman, A.; Yu, J. Blood, 2002, 100, 3319.  
[112]  Zimra, Y.; Nudelman, A.; Zhuk, R.; Rabizadeh, E.; Shaklai, M.; Aviram, A.; 
Rephaeli, A. J. Cancer Res. Clin. Oncol., 2000, 126, 693.  
[113]  Patnaik, A.; Rowinsky, E.K.; Villalona, M.A.; Hammond, L.A.; Britten, 
C.D.; Siu, L.L.; Goetz, A.; Felton, S.A.; Burton, S.; Valone, F.H.; Eckhardt, 
S.G. Clin. Cancer Res., 2002, 8, 2142. 
[114]  Göttlicher, M.; Minucci, S.; Zhu, P.; Krämer, O.H.; Schimpf, A.; Giavara, S.; 
Sleeman, J.P.; Lo Coco, F.; Nervi, C.; Pelicci, P.G.; Heinzel, T. EMBO J., 
2001, 20, 6969. 
 
[115]  Phiel, C.J.; Zhang, F.; Huang, E.Y.; Guenther, M.G.; Lazar, M.A.; Klein, 
P.S. J. Biol. Chem., 2001, 276, 36734. 
[116]  Kramer, O.H.; Zhu, P.; Ostendorff, H.P.; Golebiewski, M.; Tiefenbach, J.; 
Peters, M.A.; Brill, B.; Groner, B.; Bach, I.; Heinzel, T.; Göttlicher, M. EM-
BO J., 2003, 22, 3411. 
[117]  Kuendgen, A.; Gattermann, N. Cancer, 2007, 110, 943. 
[118]  Cloyd, J.C.; Dutta, S.; Caob, G.; Walch, J. K.; Collins, S.D.; Granneman, G. 
R. Epilepsy Res., 2003, 53, 19. 
[119]  Kelly, W.K.; Marks, P.A. Nat. Clin. Pract. Oncol., 2005, 2, 150. 
[120]  Kelly, W.K.; O’Connor, O.A.; Krug, L.M.; Chiao, J.H.; Heaney, M.; Curley, 
T.; MacGregore-Cortelli, B.; Tong, W.; Secrist, J.P.; Schwartz, L.; Richard-
son, S.; Chu, E.; Olgac, S.; Marks, P.A.; Scher, H.; Richon, V.M. J. Clin. 
Oncol., 2005, 23, 3923.  
[121]  Kelly, W.K.; Richon, V.M.; O’Connor, O.; Curley, T.; MacGregor-Curtelli, 
B.; Tong, W.; Klang, M.; Schwartz, L.; Richardson, S.; Rosa, E.; Drobnjak, 
M.; Cordon-Cordo, C.; Chiao, J.H.; Rifkind, R.; Marks, P.A.; Scher, H. Clin. 
Cancer Res., 2003, 9, 3578. 
[122]  Rosato, R.R.; Maggio, S.C.; Almenara, J.A.; Payne, S.G.; Atadja, P.; Spie-
gel, S.; Dent, P.; Grant, S. Mol. Pharmacol., 2006, 69, 216.  
[123]  Bali, P.; Pranpat, M.; Bradner, J.; Balasis, M.; Fiskus, W.; Guo, F.; Rocha, 
K.; Kumaraswamy, S.; Boyapalle, S.; Atadja, P.; Seto, E.; Balla, K. J. Biol. 
Chem., 2005, 280, 26729. 
[124]  Giles, F.; Fischer, T.; Cortes, J.; Garcia-Manero, G.; Beck, J.; Ravandi, F.; 
Masson, E.; Rae, P.; Laird, G.; Sharma, S.; Kantarjian, H.; Dugan, M.; Albi-
tar, M.; Bhalla,K. Clin. Cancer Res., 2006, 12, 4628. 
[125]  Plumb, J.P.; Finn, P.W.; Williams, R.J.; Bandara, M.J.; Romero, M.R.; 
Watkins, C.J.; La Thangue, N.B.; Brown, R. Mol. Cancer Ther., 2003, 2, 
721.  
[126]  Hess-Stumpp, H.; Bracker, T.U.; Henderson, D.; Politz, O. J. Biochem. Cell 
Biol., 2007, 39, 1388. 
[127]  Gao. S.; Mobley, A.; Miller, C.; Boklan, J.; Chandra, J. Leuk. Res., 2008, 32, 
771. 
[128]  Ryan, Q.C.; Headlee, D.; Acharya, M.; Sparreboom, A.; Trepel, J.B.; Ye, J.; 
Figg, W.D.; Hwang, K.; Chung, E.J.; Murgo, A.; Melillo, G.; Elsayed, Y.; 
Monga, M.; Kalnitskiy, M.; Zwiebel, J.; Sausville, E.A. J. Clin. Oncol., 
2005, 23, 3912. 
[129]  Gojo, I.; Jiemjit, A.; Trepel, J.B.; Sparreboom, A.; Figg, W.D.; Rollins, S.; 
Tidwell, M.L.; Greer, J.; Chung, E.J.; Lee, M.J.; Gore, S.D.; Sausville, E.A.; 
Zwiebel, J.; Karp, J.E. Blood, 2007, 109, 2781 
[130]  LoRusso, P.M.; Demchik, L.; Foster, B.; Knight, J.; Bissery, M.C.; Polin, 
L.M.; Leopold, W.R. 3rd, Corbett, T.H. Invest. New Drugs, 1996, 14, 349. 
[131]  Foster, B.J.; Jones, L.; Wiegand, R.; LoRusso, P.M.; Corbett, T.H. Invest. 
New Drugs, 1997, 15, 187.  
[132]  Prakash, S.; Foster, B.J.; Meyer, M.; Wozniak, A.; Heilbrun, L.K.; Flaherty, 
L.; Zalupski, M.; Radulovic, L.; Valdivieso, M.; LoRusso, P.M. Invest. New 
Drugs, 2001, 19, 1. 
[133]  Riva, L.; Blaney, S.M.; Dauser, R.; Nuchtern, J.G.; Durfee, J.; McGuffey, L.; 
Berg, S.L. Clin. Cancer Res., 2000, 6, 994. 
[134]  Furumai, R.; Matsuyama, A.; Kobashi, N.; Lee, K.H.; Nishiyama, M.; Naka-
jima, H.; Tanaka, A.; Komatsu, Y.; Nishino, N.; Yoshida, M.; Horinouchi, S. 
Cancer Res., 2002, 62, 4916. 
[135]  Sandor, V.; Bakke, S.; Robey, R.W., Kang, M.H.; Blagosklonny M.V.; 
Bender, J.; Brooks, R.; Piekarz, R.L.; Tucker, E.; Figg, W.D.; Chan, K.K.; 
Goldspiel, B.; Fojo, A.T.; Balcerzak, S.P.; Bates, S.E. Clin. Cancer Res., 
2002, 8, 718. 
[136]  Byrd, J.C.; Marcucci, G.; Parthun, M.R.; Xiao, J.J.; Klisovic, R.B.; Moran, 
M.; Lin, T.S.; Liu, S.; Sklenar, A.R.; Davis, M.E.; Lucas, D.M.; Fischer, B.; 
Shank, R.; Tejaswi, S.L.; Binkley, P.; Wright, J.; Chan, K.K.; Grever, M.R. 
Blood, 2005, 105, 959.  
[137]  Kuendgen, A.; Strupp, C.; Aivado, M.; Bernhardt, A.; Hildebrandt, B.; Haas, 
R.; Germing, U.; Gattermann, N. Blood, 2004, 104, 1266. 
[138]  Kuendgen, A.; Schmid, M.; Schlenk, R.; Knipp, S.; Hildebrandt, B.; Steidl, 
C.; Germing, U.; Haas, R.; Dohner, H.; Gattermann, N. Cancer, 2006, 106, 
112.  
[139]  Cimino, G.; Lo-Coco, F.; Fenu, S.; Travaglini, L.; Finolezzi, E.; Mancini, 
M.; Nanni, M.; Careddu, A.; Fazi, F.; Padula, F.; Fiorini, R.; Spiriti, M.A.; 
Petti, M.C.; Venditti, A.; Amadori, S.; Mandelli, F.; Pelicci, P.G.; Nervi, C. 
Cancer Res., 2006, 66, 8903.  
[140]  Garcia-Manero, G.; Yang, H.; Bueso-Ramos, C.; Ferrajoli, A.; Cortes, J.; 
Wierda, W.G.; Faderl, S.; Koller, C.; Morris, G.; Rosner, G.; Loboda, A.; 
Fantin, V.R.; Randolph, S.S.; Hardwick, J.S.; Reilly, J.F.; Chen, C.; Ricker, 
J.L.; Secrist, J.P.; Richon, V.M.; Frankel, S.R.; Kantarjian, H.M. Blood, 
2008, 111, 1060. 
[141]  Karon, M.; Sieger, L.; Leimbrock, S.; Finklestein, J.Z.; Nesbit, M.E.; 
Swaney, J.J. Blood, 1973, 42, 359. 
[142]  Saiki, J.H.; Bodey, G.P.; Hewlett, J.S.; Amare, M.; Morrison, F.S.; Wilson, 
H.E., Linman, J.W. Cancer, 1981, 47, 1739. 
[143]  Kornblith, A.B.; Herndon, J.E.2
nd.; Silverman, L.R.; Demakos, E.P.; Odchi-
mar-Reissig, R.; Holland, J.F.; Powell, B.L.; DeCastro, C.; Ellerton, J.; Lar-
son, R.A.; Schiffer, C.A.; Holland, J.C. J. Clin. Oncol., 2002, 20, 2441. 
[144]  Harris, N.L.; Jaffe, E.S.; Diebold, J.; Flandrin, G.; Muller-Hermelink, H.K.; 
Vardiman, J.; Lister, T.A.; Bloomfield, C.D. Hematol. J., 2000, 1, 53. 
[145]  Silverman, L.R.; McKenzie, D.R.; Peterson, B.L.; Holland, J.F.; Backstrom, 
J.T.; Beach, C.L.; Larson, R.A.; Cancer and Leukemia Group B. J. Clin. On-
col., 2006, 24, 3895. Epigenetic Treatment of Myelodysplastic Syndromes  Current Medicinal Chemistry,  2008 Vol. 15, No. 13      1287 
[146]  Sudan, N.; Rossetti, J.M.; Shadduck, R.K.; Latsko, J.; Lech, J.A.; Kaplan, 
R.B.; Kennedy, M.; Gryn, J.F.; Faroun, Y.; Lister, J. Cancer, 2006, 107, 
1839. 
[147]  Maslak, P.; Chanel, S.; Camacho, L.H.; Soignet, S.; Pandolfi, P.P.; Guernah, 
I.; Warrell, R.; Nimer, S. Leukemia, 2006, 20, 212. 
[148]  Soriano, A.O.; Yang, H.; Faderl, S.; Estrov, Z.; Giles, F.; Ravandi, F.; Cor-
tes, J.; Wierda, W.G.; Ouzounian, S.; Quezada, A.; Pierce, S.; Estey, E.H.; 
Issa, J.P.; Kantarjian, H.M.; Garcia-Manero, G. Blood, 2007, 110, 2302. 
[149]  Issa, J.P.; Garcia-Manero, G.; Giles, F.J.; Mannari, R.; Thomas, D.; Faderl, 
S.; Bayar, E.; Lyons, J.; Rosenfeld, C.S.; Cortes, J.; Kantarjian, H.M. Blood, 
2004, 103, 1635. 
[150]  Kantarjian, H.; Issa, J.P.; Rosenfeld, C.S.; Bennett, J.M.; Albitar, M.; DiPer-
sio, J.; Klimek, V.; Slack, J.; de Castro, C.; Ravandi, F.; Helmer, R. 3
rd ; 
Shen, L.; Nimer, S.D.; Leavitt, R.; Raza, A.; Saba, H. Cancer, 2006, 106, 
1794.  
[151]  Kantarjian, H.M.; O'Brien, S.; Huang, X.; Garcia-Manero, G.; Ravandi, F.; 
Cortes, J.; Shan, J.; Davisson, J.; Bueso-Ramos, C.E.; Issa, J.P. Cancer, 
2007, 109, 33.  
[152]  Rüter, B.; Wijermans, P.W.; Lübbert, M. Cancer, 2006, 106, 1744. 
[153]  Garcia-Manero, G.; Kantarjian, H.M.; Sanchez-Gonzalez, B.; Yang, H.; 
Rosner, G.; Verstovsek, S.; Rytting, M.; Wierda, W.G.; Ravandi, F.; Koller, 
C.; Xiao, L.; Faderl, S.; Estrov, Z.; Cortes, J.; O'brien, S.; Estey, E.; Bueso-
Ramos, C.; Fiorentino, J.; Jabbour, E.; Issa, J.P. Blood, 2006, 108, 3271. 
[154]  Blum, W.; Klisovic, R.B.; Hackanson, B.; Liu, Z.; Liu, S.; Devine, H.; Vu-
kosavljevic, T.; Huynh, L.; Lozanski, G.; Kefauver, C.; Plass, C.; Devine, 
S.M.; Heerema, N.A.; Murgo, A.; Chan, K.K.; Grever, M.R.; Byrd, J.C.; 
Marcucci, G. J. Clin. Oncol., 2007, 25, 3884. 
[155]  Oki, Y.; Kantarjian, H.M.; Gharibyan, V.; Jones, D.; O'brien, S.; Verstovsek, 
S.; Cortes, J.; Morris, G.M.; Garcia-Manero, G.; Issa, J.P. Cancer, 2007, 109, 
899. 
[156]  Gore, S.D.; Baylin, S.; Sugar, E.; Carraway, H.; Miller, C.B.; Carducci. M.; 
Grever, M.; Galm, O.; Dauses, T.; Karp, J.E.; Rudek, M.A.; Zhao, M.; 
Smith, B.D.; Manning, J.; Jiemjit, A.; Dover, G.; Mays, A.; Zwiebel, J.; 
Murgo, A.; Weng, L.J.; Herman, J.G. Cancer Res., 2006, 66, 6361. 
[157]  Kantarjian, H.M.; O'Brien, S.; Shan, J.; Aribi, A.; Garcia-Manero, G.; Jab-
bour, E.; Ravandi, F.; Cortes, J.; Davisson, J.; Issa, J.P. Cancer, 2007, 109, 
265.  
[158]  Burnett, A.K.; Milligan, D.; Prentice, A.G.; Goldstone, A.H.; McMullin, 
M.F.; Hills, R.K.; Wheatley, K.A. Cancer, 2007, 109, 1114. 
[159]  Aribi, A.; Borthakur, G.; Ravandi, F.; Shan, J.; Davisson, J.; Cortes, J.; 
Kantarjian, H. Cancer, 2007, 109, 713. 
[160]  Kantarjian, H.M.; O'Brien, S.; Huang, X.; Garcia-Manero, G.; Ravandi, F.; 
Cortes, J.; Shan, J.; Davisson, J.; Bueso-Ramos, C.E.; Issa, J.P. Cancer, 
2007, 109, 1133. 
 
 
Received: February 01, 2008  Revised: April 07, 2008  Accepted: April 08, 2008 
 
 